

Dual Piperidine-Based Histamine H₃ and Sigma-1 Receptor Ligands in the Treatment of Nociceptive and Neuropathic Pain

Katarzyna Szczepańska,[◇] Tadeusz Karcz,^{*,◇} Maria Dichiara, Szczepan Mogilski, Justyna Kalinowska-Thüscik, Bogusław Pilarski, Arkadiusz Leniak, Wojciech Pietruś, Sabina Podlewska, Katarzyna Popiołek-Barczyk, Laura J. Humphrys, M. Carmen Ruiz-Cantero, David Reiner-Link, Luisa Leitzbach, Dorota Łazewska, Steffen Pockes, Michał Górka, Adam Zmysłowski, Thierry Calmels, Enrique J. Cobos, Agostino Marrazzo, Holger Stark, Andrzej J. Bojarski, Emanuele Amata,^{*} and Katarzyna Kieć-Kononowicz^{*}

Cite This: *J. Med. Chem.* 2023, 66, 9658–9683

Read Online

ACCESS |




Metrics & More



Article Recommendations



Supporting Information



ABSTRACT: In search of new dual-acting histamine H₃/sigma-1 receptor ligands, we designed a series of compounds structurally based on highly active *in vivo* ligands previously studied and described by our team. However, we kept in mind that within the previous series, a pair of closely related compounds, KSK67 and KSK68, differing only in the piperazine/piperidine moiety in the structural core showed a significantly different affinity at sigma-1 receptors (σ_1 R_s). Therefore, we first focused on an in-depth analysis of the protonation states of piperazine and piperidine derivatives in the studied compounds. In a series of 16 new ligands, mainly based on the piperidine core, we selected three lead structures (3, 7, and 12) for further biological evaluation. Compound 12 showed a broad spectrum of analgesic activity in both nociceptive and neuropathic pain models based on the novel molecular mechanism.

1. INTRODUCTION

The treatment of complex, multifactorial diseases by single target-oriented therapies rarely results in good efficacy. For this reason, the approach based on the simultaneous modulation of multiple targets' activity captured the interest of the pharmaceutical industry and academia. The increasing number of evidence indicates improvement in both the therapeutic safety and efficacy of multitarget-directed ligands (MTDLs) compared with single-target drugs.^{1,2}

The histamine H₃ receptor (H₃R) is a G protein-coupled receptor (GPCR) highly expressed in the central nervous system (CNS), where it acts as an auto- and heteroreceptor to regulate neurotransmission.³ Thus, it has been considered a relevant target in the treatment of varied disorders, such as Alzheimer's disease, schizophrenia, and attention deficit hyperactivity disorder.⁴ Furthermore, being localized in several

CNS regions responsible for nociception, H₃R_s are also associated with pain⁵ through the involvement in the central sensitization of pain.

A range of competitive antagonists/inverse agonists have been discovered and progressed into clinical trials, among which pitolisant was approved in 2016 for the treatment of narcolepsy (Figure 1).^{6,7} As a consequence, the interest in the clinical application of novel H₃R antagonists, especially those with multifunctional profiles, has clearly increased.^{8–12}

Received: March 10, 2023

Published: July 7, 2023






Figure 1. Structures of selective and dual-targeting compounds evaluated in clinical trials and obtained in our previous work.²³





Figure 2. Pharmacophore models for H_3R , σ_1R , and σ_2R ligands. General structures of compounds described in this work.

Importantly, recent studies have shown that some clinically evaluated H_3R antagonists possess additional affinity at sigma-1 receptors, which may play an important role in their pharmacology and underlie the differences in the reported

preclinical and clinical efficacy.^{13,14} For example, JNJ-5207852 was highly selective for H_3R compared to the sigma-1 receptor, and the approved agent pitolisant displayed similar affinity toward both receptors (Figure 1).¹³ Therefore, sigma-1 affinity

Scheme 1. General Synthetic Pathway for Starting Ethers a–i and Compounds 1–16^a

^aReagents and conditions: (i) proper α,ω -dibromoalkane, $\text{CH}_3\text{CH}_2\text{CH}_2\text{ONa}$, 60 °C: 3 h, reflux: 3 h; (ii) proper cycloalkylamine, K_2CO_3 , KI, EtOH/ H_2O (5:1), reflux: 8–12 h.

should be always considered when interpreting the *in vivo* efficacy of novel H_3R ligands.

Sigma (σ) receptors, initially described as a subtype of opioid receptors, are now considered a separate class. Pharmacological studies have distinguished two types of σ receptors, namely, σ_1 and σ_2 .¹⁵ The sigma-1 receptor ($\sigma_1\text{R}$) is a ligand-regulated chaperone protein that modulates the signaling of proteins (receptors, enzymes) with which it interacts.¹⁶ It is a unique and poorly understood biological target engaged in physiological mechanisms of learning and memory, depression, anxiety, and schizophrenia.¹⁷ Sigma-1 antagonists are reported to be effective agents in neuropathic pain,¹⁸ and although the mechanism of action is not well understood, several studies suggest the involvement of $\sigma_1\text{Rs}$ in the regulation of ion channel function (including NMDA/GluN receptors and $\text{K}^+/\text{Ca}^{2+}$ channels), which are involved in the pathogenesis of pain.¹⁷ Many ion channels are located at the nociceptor peripheral terminal, affecting neuron excitability after injury and as a result affecting pain sensation.¹⁷ In this context, the highly selective σ_1 antagonist SIRA (Figure 1) is in phase II clinical trials for pain treatment, with an intended indication for enhancing opioid analgesia and amelioration of neuropathic pain.¹⁸

Considering the clear relation between H_3R and $\sigma_1\text{R}$, along with the fact that dual-targeting compounds can lead to several improvements when compared to selective drugs, great efforts should be made to develop such ligands for the treatment of various pain conditions. Answering this challenge, in our recent studies, we investigated 20 previously reported H_3R ligands for their affinity toward σRs to check whether their high preclinical *in vivo* efficacy is related to a synergistic effect of the dual H_3R and $\sigma_1\text{R}$ modulation.^{19–22} According to the obtained results, compounds E377 and KSK68 (Figure 1) turned out to be high-affinity histamine H_3 and σ_1 receptor antagonists with negligible affinity at the other histamine receptor subtypes and promising antinociceptive *in vivo* activity.²³ Moreover, the piperidine moiety in the basic part of those compounds has been established as a critical structural feature for dual H_3/σ_1 receptor activity as can be seen by comparing the data for compounds KSK67 and KSK68 (Figure 1). The piperidine derivatives in protonated form are involved in the essential salt bridge interaction with Glu172 in the $\sigma_1\text{R}$ binding pocket, being responsible for the high biological activity of the studied ligands. As discussed in our previous work, this phenomenon can be attributed to a change in the protonation state or states at physiological pH.²³ Therefore, in the initial step of designing

the next series of ligands, we focused on an in-depth analysis of the protonation states of piperazine vs piperidine derivatives using crystallography, potentiometric titration, and NMR spectroscopy measurements in a pH-controlled environment. Next, we designed a series of 16 new compounds, mainly based on the piperidine core, with the general structure presented in Figure 2 and performed their pharmacological characterization using *in vitro* methods. Finally, lead compounds were tested in animal models of nociceptive and neuropathic pain.

2. RESULTS AND DISCUSSION

2.1. Chemistry. The synthesis of the desired final compounds 1–16 was achieved through the synthetic route presented in Scheme 1. According to the previously described procedure,^{19,21,22,24,25} the phenoxy alkyl bromides a–i were obtained mainly by one-step alkylation of commercially available phenols with 1,3-dibromopropane (a–e), 1,4-dibromobutane (f, i), 1,5-dibromopentane (g), or 1,6-dibromohexane (h) in propan-1-ol under reflux conditions. Obtained precursor bromides were then coupled with 3-methylpiperidine (1), 4-methylpiperidine (2), azepane (3), pyrrolidine (4), piperidine (5–11), 4-(piperidin-4-yl)pyridine (12–15), or 2-(piperazin-1-yl)pyrazine (16) in a mixture of ethanol/water with powdered potassium carbonate and a catalytic amount of potassium iodide. The final products were obtained as free bases and isolated as oxalate or hydrogen oxalate salts.

2.2. Protonation Investigation Based on Crystal Structure Analysis. To determine the potential differences in the protonation of piperidine and piperazine derivatives, we selected two pairs of compounds for crystallographic studies, differing only in the basic part. The first contains the cyclopropylmethanone derivatives KSK67 and KSK68 obtained in our previous work^{22,23} (Figure 1), whereas the second contains two nitrile derivatives: KSK94 (also published earlier,^{22,23} Figure 1) and compound 12 (structure in Pharmacology, Table 2). In the KSK67 and KSK68 oxalate crystals, the total charge of the main organic compound is +2, with protonation centers at N1 (pyridine) and N10 (piperazine/piperidine) nitrogen atoms. The resulting positive charge is compensated by oxalate anions that form charge-assisted hydrogen bonds with the mentioned protonated amine (Figures S1 and S2). An interesting geometry is observed for N1–H–O3A interaction in structure KSK68 (distances: N1...O3A 2.581 Å, N1–H 1.305 Å, O3A–H 1.278 Å; angle: N1–H–O3A 175.66°), suggesting possible proton transfer between




Figure 3. The geometrical parameters of the strongest interactions observed in the crystal structure of **KSK68** (charge-assisted hydrogen bonds $N^+ \cdots H \cdots O^-$ type; distances in dark blue, angles in light green). The weaker basicity of the N1 atom in the pyridine ring is manifested by the hydrogen shift toward oxalate anion (discussed fragment is depicted with a dashed-line ellipsoid). Displacement ellipsoids of nonhydrogen atoms are drawn at the 30% probability level. H atoms not involved in the described interactions were removed for figure clarity.

Table 1. Selected Geometrical Parameters Defined for the Determined Crystal Structures^a

Geometrical parameter	Structure								
	KSK67	KSK68	KSK68_OH	KSK67_fb	KSK68_fb	KSK94_fb		12_fb	
(mol. total charge)	(+2)	(+2)	(+1)	(+1)	mol. 1 (0)	mol. 2 (0)	mol. 1 (+1)	mol. 2 (0)	(0)
C4-N7/C7	1.350 Å	1.508 Å	1.511 Å	1.340 Å	1.514 Å	1.518 Å	1.351 Å	1.360 Å	1.507 Å
N10-C13	1.543 Å	1.492 Å	1.543 Å	1.477 Å	1.467 Å	1.469 Å	1.460 Å	1.481 Å	1.464 Å
C4-N7/C7-C8	124.00°	109.82°	110.75°	123.43°	109.76°	115.00°	120.22°	119.42°	111.97°
C4-N7/C7-C12	125.95°	112.11°	114.68°	124.24°	115.59°	110.96°	119.95°	118.96°	113.78°
C8-N7/C7-C12	110.05°	109.92°	108.22°	110.89°	107.92°	108.25°	115.15°	115.86°	108.93°
C3-C4-N7/C7-C8	-0.92°	-65.58°	-92.40°	5.92°	15.12°	-74.31°	169.53°	-14.11°	129.33°
C5-C4-N7/C7-C12	-1.47°	-124.30°	-35.46°	-10.16°	70.06°	-19.69°	-166.79°	14.98°	72.41°
N1...N10	6.881 Å	7.031 Å	7.131 Å	6.982 Å	7.079 Å	7.105 Å	7.037 Å	7.033 Å	7.107 Å
N10...C _{tp}	5.545 Å	5.684 Å	5.753 Å	5.629 Å	5.705 Å	5.727 Å	5.658 Å	5.633 Å	5.719 Å
N10...N7/C7...C _{tp}	155.78°	150.40°	155.94°	168.00°	151.68°	153.78°	174.79°	171.98°	155.57°

^aC_{tp}: geometrical center of the pyridine ring.

pyridine nitrogen N1 and O3A of the carboxylic group (Figure 3). That may imply weaker basic properties of N1 compared to the piperidine N10 protonation center for **KSK68**. This can be deduced also based on the obtained **KSK68_OH** crystal structure, where increased pH led to +1 cation, with sole protonation at N10 (Figure S3).

The crystal structures obtained for the free bases **KSK67_fb**, **KSK68_fb**, **KSK94_fb**, and **12_fb** from water/organic solvents revealed peculiar properties of molecules with 4-pyridylpiperazine moiety. Surprisingly, molecules containing the mentioned fragment (**KSK67_fb** and **KSK94_fb**) did not crystallize in the neutral form. The pyridine nitrogen of those compounds is a very strong base and easily protonates in the solution (Figures S4 and S6). Thus, in the crystal, an iodide salt is observed. The counter ion I⁻ was introduced during the synthesis, where the catalytic amount of potassium iodide was applied (see Chemistry Section 2.1.). An analogous basic property of N1 is not observed for **KSK68_fb** and **12_fb** with

4-pyridylpiperidine moiety. For these samples, crystals with the neutral form of the compound were obtained (Figures S5 and S7).

The observed strong basic character of N1 in structures **KSK67_fb** and **KSK94_fb** is a consequence of the increased availability of lone pair electrons correlated with the electron source at the para position (lone pair of N7 nitrogen atom of the piperazine ring). The N7-lone pair shift manifests in N7-C4 bond shortening to ~1.35 Å (Table 1), which implies a partial double bond character and decreasing pyramidalicity of N7 atom. The last observation is confirmed by angles C4-N7-C8 and C4-N7-C12 being ~120° (Table 1) and defining nearly flat geometry around N7. The observed change of N7 hybridization from sp³ to sp² leads to the quasi-planar mutual orientation of pyridine and piperazine (torsion angles C3-C4-N7-C8 and C5-C4-N7-C12 closer to 0/180°; Table 1). Such effect and geometry are often observed for arylpiperazine or




Figure 4. Structure and experimental pK_a values of KSK compounds and corresponding amino alcohols.




Figure 5. The protonation states of KSK68 and KSK94 as a function of pH. The species distribution was generated from the CerkoLab software based on titration curves of investigated compounds (see Figure S8). The equilibria between the species are as follows: KSK68: $H_2L^{+2} = H^+ + HL^+$, $pK_1 = 4.94$ and $HL^+ = H^+ + L^0$, $pK_2 = 8.38$; KSK94: $H_2L^{+2} = H^+ + HL^+$, $pK_2 = 6.25$ and $HL^+ = H^+ + L^0$, $pK_2 = 6.65$.

heteroatoms in the aromatic fragment.²⁶ Nevertheless, the observed phenomenon is responsible for the rigidity of the 4-pyridylpiperazine fragment that determines the highly basic character of N1 as well as the orientation of π -electrons of the aromatic fragment. This last characteristic may be a strong geometrical feature responsible for effective ligand–protein recognition and may explain the observed selectivity of the investigated compounds containing the 4-pyridylpiperazine fragment for H_3R .

2.3. Determination of the Basicity of Selected Piperidine and Piperazine Derivatives by Potentiometric Titration. Several key physicochemical properties that influence absorption and distribution processes, such as lipophilicity and solubility, depend on pK_a . The ionization state is a key parameter not only in ADME profiling but also during ligand–receptor mutual recognition and interaction, as it usually occurs in an aqueous environment at physiological pH.

Thus, we evaluated two representative compounds, KSK68 and KSK94, containing a piperidine or piperazine substituted with a 4-pyridyl moiety in pK_a studies. In addition, we tested the amino alcohol fragments of these compounds to carefully monitor the influence of individual protonated nitrogen atoms

on the obtained pK_a values (Figure 4). Considering the structural differences between KSK68 and KSK94, it seems obvious that their different binding potency toward σ_1R should be attributed to the change in protonation state at physiological pH. Based on a previously modified potentiometric procedure,^{27,28} a series of titrations were performed, and the pK_a values were determined using the Kostrowicki and Liwo algorithm.^{29,30} Experimental pK_a data show that KSK68 exists exclusively in the monoprotonated form in an aqueous solution at physiological pH (approximately 90% of $[HL^+]$ form, Figure 5). That explains the surprising result of free base crystallization attempts where iodide salt was obtained instead of the neutral form. On the other hand, in the same environment, KSK94 exists in two forms: the monoprotonated form $[HL^+]$ (20.56%) and the free ligand $[L]$ (77.72%, Figure 5). Experimental data show how replacing the piperidine system with a piperazine ring drastically affects the acid–base properties of the molecule. KSK68 can be characterized as a basic ligand with $pK_{a1} = 4.9$ (pyridine N) and $pK_{a2} = 8.4$ (piperidine N). The pK_a values are consistent with those determined by the same procedure for the corresponding amino alcohol 3-(4-(pyridin-4-yl)piperidin-1-yl)propan-1-ol (Figure 4). In contrast to KSK68, the KSK94 compound




Figure 6. NMR titration experiment for **KSK68** presents stacked ^1H NMR spectra of (1a) the aromatic region of chemical shifts and (2a) the aliphatic one. The concentration of acid is rising in an upward direction by 0.2 molar equivalents. (1b, 2b) Graphs that represent the change in the chemical shift of the individual signals on the ^1H NMR spectra as the concentration of triflic acid in the solution increases. Panel 1b corresponds to the aromatic region of chemical shifts and 2b to the aliphatic one. The colors on the top structure of **KSK68** refer to the signals marked on the spectra with exact color lines and to the colors of the lines on the graphs. The largest changes in the difference in chemical shifts $\Delta\Delta\delta$ are observed for signals of protons that are adjacent to the nitrogen atoms, which undergo protonation. Tracking these changes in $\Delta\Delta\delta$ while increasing the concentration of triflic acid in the solution allows one to assess the order of protonation of individual nitrogen atoms in the molecule (when nitrogen functions possess significant difference in $\text{p}K_a$) and determine the integer number of nitrogen atoms that undergo protonation. For a detailed analysis, see the [Supporting Information](#).

belongs to the group of ligands with an acidic center located at the N7 nitrogen of the piperazine ring with a $\text{p}K_{a2}$ value of approximately 1 ([Figure 4](#)). A similarly low $\text{p}K_{a2}$ value for the N7 piperazine nitrogen atom was also determined for the corresponding amino alcohol 3-(4-(pyridin-4-yl)piperazin-1-yl)propan-1-ol ([Figure 4](#)), which is in agreement with the value obtained for 1-phenyl-4-methyl piperazine reported in the literature.³¹ Moreover, the literature $\text{p}K_a$ values of 1-aryl-4-propylpiperazines range from 7.59 to 8.39 for the $\text{N-CH}_2\text{-CH}_2$ moiety. The lowest value was determined for 4-nitrophenyl, and the highest was for 2-methylphenyl derivatives.³²

2.4. Protonation Investigation Based on NMR Spectroscopy Measurements in the pH-Controlled Environment. Another attempt to determine the order of protonation of nitrogen atoms in studied molecules was carried out using NMR spectroscopy.

All signals in the ^1H and ^{13}C spectra were assigned based on 2D correlation spectra for compounds **KSK68** and **KSK94** (piperidine and piperazine derivatives, respectively) to follow the course of changes in their chemical shifts during titration with trifluoromethanesulfonic acid (triflic acid or TfOH), one of the strongest organic acids ($\text{p}K_a \sim (-15)$). A detailed description of the chemical shifts upon the addition of triflic acid is described in the [Supporting Information](#).

In the case of **KSK68**, the nitrogen atom in the piperidine ring is protonated first ([Figure 6](#)). Protonation of the nitrogen atom in the pyridine ring begins after full saturation to a molar ratio of 1.0:1.0. This is clearly visible in the shifts of protons in the vicinity of individual nitrogen atoms. The sole signal on the spectrum that shifts toward higher frequencies during the titration process comes from the H3 proton, which is located near both nitrogen atoms and links the two rings. The observed effect is characteristic for systems in which the $\text{p}K_a$




Figure 7. NMR titration experiment for KSK94 presents stacked ^1H NMR spectra of (1a) the aromatic region of chemical shifts and (2a) the aliphatic one. The concentration of acid is rising in an upward direction by 0.2 molar equivalents. (1b, 2b) Graphs that represent the change in the chemical shift of the individual signals on the ^1H NMR spectra as the concentration of triflic acid in the solution increases. Panel 1b corresponds to the aromatic region of chemical shifts and 2b to the aliphatic one. The colors on the top structure of KSK94 refer to the signals marked on the spectra with exact color lines and to the colors of the lines on the graphs. The largest changes in chemical shifts $\Delta\Delta\delta$ are observed for signals of protons that are adjacent to the nitrogen atoms, which undergo protonation. Tracking these changes in $\Delta\Delta\delta$ while increasing the concentration of triflic acid in the solution allows one to assess the order of protonation of individual nitrogen atoms in the molecule (when nitrogen functions possess significant difference in $\text{p}K_a$) and determine the integer number of nitrogen atoms that undergo protonation. For a detailed analysis, see the [Supporting Information](#).

values for the two basic centers differ significantly. Here, the $\text{p}K_a$ for piperidine nitrogen is higher in value than that for pyridine nitrogen, which is in line with the theoretical data.

For KSK94, the model is more complicated than for KSK68 (Figure 7). H1, H2, and H3 protons are affected by a change in the chemical environment at first, with H2 protons being the least affected. Thus, the proton environment is mostly changed in the proximity of the pyridine nitrogen atom and near the piperazine nitrogen closer to the pyridine. Taking further into account the difference of 94 ppm in ^{15}N chemical shift for pyridine nitrogen, it can be concluded that the nature of the pyridine nitrogen atom changes dramatically from purely aromatic to an intermediate form between heterocyclic and amine. As a consequence, the pyridine nitrogen atom is protonated first, but the positive charge is transferred to the piperazine nitrogen atom by appropriate resonance structures. The second piperazine nitrogen atom is initially unprotonated,

as indicated by no change in the chemical shift of proton signals from its immediate vicinity. From an acid molar ratio of 0.6:1.0, protonation of the second nitrogen atom in the piperazine ring can be observed. The proton signals in the vicinity of this nitrogen atom broaden by losing multiplicity and start to move toward higher frequencies. This is analogous to the first protonation step of KSK68. At this point, both nitrogen functions protonate at the same time, as both the aromatic and aliphatic proton signals shift toward higher frequencies, indicating similar $\text{p}K_a$ values, with the value of the first stage being higher. Because of the loss of one symmetry element and likely conformational stiffening of the piperazine ring, the signals from the H3 and H4 protons, which were integrated as four protons, split into axial and equatorial components, and now each is integrated as two. At a ratio of 1.4:1.0, saturation occurs, and no further changes were observed despite reaching the molar ratio of 3:0:1.0.

Table 2. Structures of Compounds 1–16 and Their *in Vitro* Binding Affinities at the Human Histamine H₃ Receptor (hH₃R) and Rat Sigma-1 (σ_1 R) and Sigma-2 (σ_2 R) Receptors^f

Compound	n	R ¹	R ²	\bar{x} [CI 95%]			
				hH ₃ R K_i [nM]	σ_1 R K_i [nM]	σ_2 R K_i [nM]	σ_2/σ_1 ratio
1	1		phenyl	31 [11, 90]	1.5 [0.5, 4.1]	17 [9, 32]	11.3
2	1		phenyl	10.3 [1.7, 62.4]	2.4 [0.7, 8.2]	16 [12, 22]	6.7
3	1		phenyl	4.3 [1.4, 13.0]	1.9 [0.6, 5.8]	25 [7.6, 83]	13.2
4	1		phenyl	19.5 [4.7, 81.2]	24 [8.4, 66]	65 [34, 128]	2.7
5	1		4-cyanophenyl	6.2 [1.5, 26] ^a	28 [5.7, 136]	47 [21, 105]	1.7
6	1		phenoxy	2.7 [1.1, 5.8]	18 [8.2, 39]	103 [48, 223]	5.7
7	1		N-phenylamine	5.2 [2.1, 12.6]	4.8 [2.8, 8.4]	116 [70, 191]	24.2
8	1		benzyl	27.5.0 [9.1, 83.4]	5.5 [1.1, 27]	47 [22, 102]	8.5
9	2		phenyl	22 [7, 73]	95 [36, 252]	33 [14, 74]	0.3
10	3		phenyl	21.7 [3.9, 110] ^b	140 [78, 251]	19 [8.8, 41]	0.1
11	4		phenyl	88.9 [42, 187] ^b	118 [31, 449]	46 [18, 114]	0.4
12	1		4-cyanophenyl	7.7 [1.1, 52.5]	4.5 [1.3, 15]	10 [5.6, 20]	2.2
13	1		phenoxy	24.2 [3.1, 187.6]	5.6 [2.8, 11]	4 [0.8, 19]	0.7
14	1		N-phenylamine	69 [18.8, 253.4]	3.3 [1.6, 7.1]	29 [14, 59]	8.8
15	1		benzyl	76.1 [18.4, 315.7]	2.8 [1.3, 6]	9.9 [3.6, 27]	3.5
16	2		<i>tert</i> -butyl	5477 [1034, 29027] ^c	7.6 [4, 14]	27 [11, 67]	3.6
Pitolisant				11.2 [6.7, 18.4]	0.5 ^d	6.5 ^d	13
(+)-Pentazocine					4.3 ^e	1465 ^e	340.7
DTG					124 ^e	18 ^e	0.1

^aData published in ref 25. ^bRecalculated from data published in ref 24. ^cData published in ref 19. ^dData published in ref 7. ^eData published in ref 61. ^fGiven data represent mean values within the 95% confidence interval (CI).

2.5. In Vitro Pharmacology. **2.5.1. Affinity at H₃R and σ Rs.** *In vitro* affinity data for the newly synthesized ligands are assembled in Table 2. Interestingly, almost all compounds (except 16) showed high affinity at histamine H₃ receptors with K_i values below 100 nM. Moreover, all the described ligands showed more or less significant activity to both sigma

receptors but with different binding affinities. In the case of compound 16, the only piperazine derivative in this series, the lack of activity toward H₃R is related to the pyrazine-2-yl group in the basic part of the molecule, as discussed in our previous work.^{19,20} Nevertheless, 16 was still very active on both sigma receptors (σ_1 R K_i = 7.6 nM, σ_2 R K_i = 27 nM). The

unsubstituted piperidine ring in the basic part of the compounds seems to be the most influential on affinity at human H₃R (hH₃R), as can be seen by comparing compounds 5–7 with their 4-pyridyl analogues 12–14 (hH₃R K_i = 6.2, 2.7, and 5.2 nM vs 7.7, 24.2, and 69 nM, respectively). Moreover, this structural relationship is also observed in the case of ligands 1 and 2, which are methyl analogues of the lead compound E377 (Figure 1) published in our previous paper²³ (hH₃R K_i = 31 and 10.3 nM vs 6.2 nM, respectively). However, for both sigma receptors, 4-pyridylpiperidine derivatives 12–14 were more potent than unsubstituted piperidines (5–7), especially when comparing affinity values toward sigma-1 receptors (σ_1 R K_i = 4.5, 5.6, and 3.3 nM vs 28, 18, and 4.8 nM, respectively; σ_2 R K_i = 10, 4, and 29 nM vs 47, 103, and 116 nM, respectively). For all the described piperidine derivatives, the effect of the alkyl chain can only be observed at the H₃R, where the extension of the linker length decreased the affinity of biphenyl analogues 9, 10, and 11 (hH₃R K_i = 22, 21.7, and 88.9 nM, respectively). In our previous work, we found a critical structural feature that distinguishes the dual H₃/ σ_1 R ligands and selective H₃R-targeting compounds.²³ One of the lead structures, KSK68 with the 4-pyridylpiperidine moiety as the fundamental part of the molecule, showed high affinity at both histamine H₃ and σ_1 receptors, whereas its piperazine analogue KSK67 was highly selective for H₃R (Figure 1). Interestingly, this time, we also confirmed this structural phenomenon, as can be seen by comparing the nitrile derivative 12 with its piperazine analogue KSK94 described in our previous work (Figure 1, hH₃R K_i = 7.7 nM and σ_1 R K_i = 4.5 nM vs hH₃R K_i = 7.9 nM and σ_1 R K_i = 2958 nM, respectively). Again, the piperidine derivative 12 showed dual H₃/ σ_1 R activity, whereas the piperazine-based compound KSK94 was highly selective for H₃R. Taking into account the selectivity toward sigma-2 receptors in the group of biphenyl derivatives with three-carbon chains, the highest values were observed for compounds 1 and 3 (σ_2/σ_1 ratio 11.3 and 13.2, respectively). Furthermore, extending the carbon chain from four to six methylene groups significantly reduced this parameter (ligands 9–11). Aniline derivative 7 showed the highest σ_2/σ_1 ratio among all described derivatives (24.2).

As lead structures for further evaluation, we selected two piperidine derivatives, 3 and 7, with high affinity at both H₃R and σ_1 R as well as the highest σ_2/σ_1 selectivity factor. In this choice, we were guided by the fact that the highly selective σ_1 R antagonist SIRA, so far the only one tested in clinical trials for pain treatment, showed no affinity at σ_2 R.¹⁸ On the other hand, bearing in mind recently reported studies with novel σ_2 R-selective ligands, which suggest that they may also modulate nociception,³³ we included nitrile derivative 12 exhibiting activity toward σ_2 R at a comparable level as toward H₃R and σ_1 R. Moreover, its piperazine analogue, compound KSK94, was extensively tested in the obesity model in our previous studies and showed a good safety profile.²²

2.5.2. Affinity at Other Histamine Receptors. To check the selectivity profile of our lead structures, radioligand binding studies at other histamine receptor subtypes were carried out. Compounds 3, 7, and 12 in their oxalate forms were tested at human recombinant histamine H₁, H₂, and H₄ receptor subtypes stably expressed in HEK293T cells. Obtained results clearly indicate the high selectivity of the tested derivatives toward human H₃R (Table 3).

2.5.3. Intrinsic Activity toward H₃R. To identify the lead compounds' functional profile, their intrinsic activity was

Table 3. Radioligand Binding Assay at Human Histamine H₁ (hH₁R), H₂ (hH₂R), and H₄ (hH₄R) Receptors and Functional Study at the Human Histamine H₃ Receptor (hH₃R)^a

compound	hH ₁ R (K _i [nM] \bar{x} [CI 95%])	hH ₂ R (K _i [nM] \bar{x} [CI 95%])	hH ₄ R (K _i [nM] \bar{x} [CI 95%])	hH ₃ R (IC ₅₀ [nM] \pm SD)
3	7615 [4024; 14,407]	>10,000	>10,000	83.4 \pm 15.9
7	>10,000	>10,000	>10,000	83.7 \pm 2.1
12	653 [259; 1647]	>10,000	>10,000	215 \pm 108
thioperamide				375 \pm 30
pitolisant				1.96 \pm 0.80

^aGiven data represent the mean K_i (nM) values within the 95% confidence interval (CI) ($n = 3$, triplicate) or the mean IC₅₀ values of tested compounds in the cAMP assay \pm standard deviation ($n = 2$, triplicate).

tested in a 3',5'-cyclic adenosine monophosphate (cAMP) accumulation assay in HEK cells expressing human recombinant H₃R.³⁴ All tested compounds reversed the R- α -methylhistamine inhibition of cAMP production in forskolin-stimulated cells and were therefore classified as H₃R antagonists/inverse agonists. The IC₅₀ values obtained in the H₃R functional assay are assembled in Table 3.

2.6. In Silico Studies. Molecular Modeling: Docking Studies and Molecular Dynamics Simulations. In addition to experimental studies, the protonation states of compounds were also evaluated *in silico* using two software packages: InstantJChem and Epik (Figure 8). Although there are slight differences in the numerical values of predicted pK_a, the overall tendencies observed for the performed experiments are preserved: nitrogen atoms belonging to the piperidine moieties are characterized by higher pK_a values than those of piperazine, and therefore, they are less likely to protonate at physiological pH.

To further investigate the influence of structural differences between the 4-pyridylpiperazine and 4-pyridylpiperidine moieties on their molecular mechanism of action, the binding with sigma-1 and histamine H₃ receptors was evaluated using molecular modeling methods. Analysis of the binding mode of KSK94 and 12 to σ_1 R shows coherent binding modes of 4-pyridylpiperidine/piperazine fragment in comparison to our previous studies^{22,23} (Figure 9A). However, because of the use of induced-fit docking, which allows relaxing the binding pocket and fitting of adjacent amino acids to the molecular core of compounds, we observed that the 4-cyanophenyl fragment occupies a hydrophobic pocket with the stabilizing hydrogen bond (HB) between the nitrile group and the main chain of Ser99. Then, on the basis of both NMR analysis and crystallographic results, we decided to dock all protonation and tautomeric states of KSK94 and 12 using *ab initio* docking (quantum polarized ligand docking, QPLD) and energy calculations applying the Molecular Mechanics Generalized Born Surface Area (MM-GBSA) method (Table S5, SI). First, we estimated the energy loss of piperazine derivatives to piperidine ones for σ_1 R. The result showed that the tautomeric monoprotonated pyrimidine structure (the most populated protonation state) of KSK94 has a higher ΔG value vs 12 (Table 4), indicating a loss of ligand–receptor interaction energy, which is also reflected in the *in vitro* results (Table 2). In the case of the monoprotonated tautomeric form, a loss of




Figure 8. Results of *in silico* protonation studies of compounds KSK67, KSK68, KSK94, and 12.




Figure 9. Comparison of the binding mode of KSK94 (green) in tautomeric monoprotinated state and 12 (yellow) in the σ_1 R (PDB ID: 6DJZ) (A). Comparison of the binding mode of KSK67 (green) in the tautomeric monoprotinated state and KSK68 (yellow) in the H_3 R binding site (homology model) (B). The corresponding salt bridges are marked in red and magenta.

Table 4. Comparison of Free Binding Energies and Docking Scores of the Most Populated Protonation States with the *In Vitro* Activity of KSK67, KSK68, KSK94, and 12 with σ_1 and H_3 Receptors

Form	Compound	σ_1 R			H_3 R		
		K_i [nM]	Docking score	ΔG [kcal/mol]	K_i [nM]	Docking score	ΔG [kcal/mol]
	KSK67	1531	-8.04	-61.24	3.2	-9.67	-98.11
	KSK94	2958	-10.45	-81.44	7.9	-10.22	-95.71
	KSK68	3.6	-9.56	-99.29	7.7	-10.79	-98.69
	12	4.5	-11.51	-99.47	7.7	-10.47	-97.64

the essential salt bridge interaction with Glu172 (Figure 9A) can explain the decrease in biological activity. A similar correlation between *in vitro* results and ΔG value can be noticed for KSK67 and KSK68 compounds (Table 4). When analyzing the interactions of lead compounds, it is worth noting that ligands 3 and 7 occupy exactly the same place as 12 despite the lack of a heteroaromatic ring connected to the saturated basic fragment (Figure S25). Notably, enriched by the assembled experimental evidence and observations, in this study, more complex and sophisticated molecular modeling

methods were applied compared to the previous studies,²³ resulting in different binding modes observed. Analysis of the previously described KSK68 binding mode showed significant changes compared to the results presented here, where a salt bridge with Asp114 (D3.32) was formed. However, the two compound poses are flipped with respect to each other. In our earlier studies, the conformation of KSK68 was almost linear (Figure S24), whereas in the current study, the conformation resembles the one observed for the sigma-1 receptor (Figure 9A,B). In fact, four distinct binding modes of H_3 R ligands have

been reported so far in the literature;^{35–44} however, we decided to focus on the one that does not involve Glu206. This orientation was also similar to the alternative binding modes of ciproxifan in the H₃R binding pocket.^{37,45} Because of the expansion of the tertiary amine fragment compared to ciproxifan (replacement of imidazole with 4-pyridylpiperazine), compound **12** additionally forms contacts with Tyr91 (TM3), Tyr394 (TM7), as well as Glu395 (TM7). To explain the slight difference in the biological activity of **KSK94** and **12** toward H₃R (Table 2), *ab initio* molecular docking of all protonation and tautomeric forms was performed (Table S5, SI). The results showed that for the monoprotonated tautomeric form of **KSK94**, the loss of the ligand–receptor interaction energy (ΔG) is insignificant (Table 4), which is related to formation of an additional stabilizing salt bridge with Glu395, which also correlates with the biological activity observed. Moreover, the compounds occupy the same region of the binding pocket, and because of the nature of the homology modeling procedure applied to generate the H₃R model, alternative binding mechanisms cannot be excluded. For the monoprotonated tautomeric form of **KSK67**, compared to **KSK68**, the ΔG values are close, which correlate well with the experimental results (Table 4). The observed salt bridge with D3.32 (the strongest interaction in ligand–receptor interactions)⁴⁶ fixes the position occupied by the ligands, which can be seen by comparing lead compounds **3** and **7** (Figure S26). The *N*-phenylamine (**7**) or phenyl (**3**) fragment penetrates deep into the binding pocket because of its hydrophobic environment and, as with compound **12**, interacts through hydrophobic effects or π – π stacking interactions (Figure S26).

To confirm the validity of the docking poses discussed above, the molecular dynamics (MD) simulations were carried out. The obtained data were analyzed both in terms of the variation in the ligand–protein contacts as well as *via* the examination of ligands' RMSDs. Both approaches confirmed the stability of the obtained docking poses: the compounds occupied the same region of the binding pocket during the whole simulation process, and the patterns of ligand–protein interactions in general remain the same (Figures S27 and S28).

We are aware of the H₃R crystal structure, which was released in late October 2022 in the PDB repository (PDB ID: 7F61).⁴⁷ The crystalized complex contains an antagonist in the binding pocket, PF03654746, as well as the unexpected cholesterol binding at the allosteric site. According to the authors, the H₃R orthosteric binding pocket is shallow, and PF03654746 occupies an extended part of it (EBD). To evaluate the quality of our homology model, we docked PF03654746 to the model, and we obtained a similar pose to that observed in the crystal structure (Figure S29). The RMSD (root-mean-square deviation) of ligands was 1.48 Å, and it is less than the crystal resolution (2.6 Å), which indicated that our model was coherent with the crystal structure. It is worth to stress that the proposed binding mode of KSK ligands engaged the same protein helices (especially TM7) and crucial amino acids.⁴⁷ For this reason, we decided not to perform *in silico* calculations once again using an experimental H₃R structure.

2.7. Determination of Selected ADMET Parameters.

2.7.1. Permeability Profile. During the research and development of new drugs directed to the central nervous system, there is a considerable attrition rate caused by their hampered access to the brain by the blood–brain barrier. Throughout the

years, several *in vitro* models have been developed in an attempt to mimic critical functionalities of the blood–brain barrier and reliably predict the permeability of drug candidates. Therefore, the ability of selected compounds (**3**, **7**, **12**, and **SIRA**) to penetrate across lipid membranes was estimated by a parallel artificial membrane permeability assay (PAMPA). In medicinal chemistry, PAMPA is a method that determines the permeability of substances from a donor compartment through a lipid-infused artificial membrane into an acceptor compartment; passive diffusion is the predominant absorption mechanism of most commercial drugs.⁴⁸ By using UPLC–MS with an internal standard, the exact quantity of molecules that penetrated from donor to acceptor wells through the phospholipid membrane was measured. The results were expressed as permeability coefficient P_e calculated according to the formulas described in the literature.⁴⁹ Taking into account the collected data and comparing them with two standards: well-permeable caffeine ($P_e = 10.49 \times 10^{-6}$ cm/s) and low-permeable sulphiride ($P_e = 0.05 \times 10^{-6}$ cm/s), it seems justified to consider the tested molecules as substances with highly passive transport through biological membranes (Table 5). In

Table 5. PAMPA Results (Permeability Coefficient P_e) for Tested Compounds

compound	P_e (10^{-6} cm/s)
SIRA	5.26
3	6.57
7	10.63
12	12.00
caffeine	10.49
sulpiride	0.05

general, compounds with a P_e value above 4×10^{-6} cm/s are considered permeable, whereas those with a lower value are considered impermeable. All tested ligands showed P_e values greater than the threshold value.

Moreover, taking into account an intracellular localization of sigma receptors, the high ability of tested compounds to penetrate lipid membranes and, at the same time, the possibility of interacting with σ_1 R seem to be an important feature of dual histamine H₃/ σ_1 R ligands.

2.7.2. Serum Metabolic Stability. A successful drug-lead candidate must possess favorable characteristics, including, among others, good serum stability; therefore, we decided to test this parameter for compound **12**. Using LC–MS with imipramine as an internal standard, the exact amount of molecule remaining in the serum was measured at six time points (0, 1, 2, 4, 6, and 24 h) for three initial concentrations (0.1, 0.5, and 1 μ M). The response ratio was calculated by dividing the test peak area by the internal standard peak area and converted to % of test compound remaining in the serum. The % of test compound remaining was then plotted vs time (Figure 10). Upon the curve fitting using a one phase decay model, the half-life parameter was calculated to characterize the serum stability of compound **12** ($t_{1/2} = 7.7 \pm 1.4$ h). As a reference drug, we used highly stable atenolol at an initial concentration of 1 μ M. The % of atenolol remaining in the serum after 24 h of incubation was significantly higher than compound **12** (82.3 vs 17.5%); thus, **12** can be considered a moderately stable ligand.

2.8. In Vivo Pharmacological Activity. **2.8.1. Safety Pharmacology: Influence of Lead Compounds on Sponta-**




Figure 10. Serum stability of compound **12**. The % of test compound remaining in the serum is plotted vs time, and the curve is fitted using a one phase decay model.

neous Locomotor Activity and Motor Coordination in the Rotarod Test. The high sedative activity of analgesics is considered an undesirable property, which may lead to an incorrect or ambiguous interpretation of the *in vivo* results. Moreover, it may limit the potential clinical application of new drug candidates. Therefore, we tested the influence of compounds **3**, **7**, and **12** on spontaneous locomotor activity to investigate their sedative properties. The data presented in Figure S30 indicate that compounds **3** and **7** at the dose of 15 mg/kg showed high and significant sedative effects ($F_{(2,21)} = 28.36$; $p < 0.0001$). In contrast, **12** at the same dose decreased spontaneous locomotor activity, but the effect was not statistically significant, which proved the less pronounced sedative property of this compound. It significantly decreased locomotor activity at the dose of 30 mg/kg ($F_{(3,32)} = 4.97$; $p < 0.01$). The estimated ED_{50} value for the ligand in this test was 21.97 mg/kg (Figure S31).

The neurotoxicity of the new compounds can result in impaired motor functions of the experimental animals, which may subsequently cause false interpretation of the results of *in vivo* tests. Understandably, neurotoxicity is also the frequent reason for eliminating the tested compound from further studies. To minimize that risk, we investigated the influence of our lead structures on motor coordination in the rotarod test, which is the classical test used for assessing motor coordination and balance in rodents. It provides a quick and simple estimation of neuromuscular coordination. During our test, the vehicle-treated mice did not demonstrate any signs of impaired motor coordination. The time spent on the rotarod apparatus was 60 s for each control mouse. Compound **7** at the dose of 15 mg/kg significantly decreased the time spent on the rod at 18 and 24 rpm ($F_{(3,20)} = 31.32$; $p < 0.0001$). Although the effect of **3** was less pronounced, the compound also significantly impaired the motor coordination of mice at the administrated dose (15 mg/kg) and two tested speeds (18 and 24 rpm) ($F_{(3,20)} = 3.33$; $p < 0.05$). Compound **12** at the same conditions slightly affected motor coordination, but the effect was not statistically significant ($F_{(3,20)} = 2.31$; $p = 0.107$) (Figure S32). The results showed that **12** is characterized by a better safety profile than the other two tested compounds.

2.8.2. Antinociceptive Activity in the Formalin Test. The formalin test is one of the most useful screening models for testing potentially clinically relevant antinociceptive molecules because of its ease of administration, standardization, and

validation with reference drugs.⁵⁰ The subcutaneous injection of formalin results in a focal injury that stimulates and then damages sensory endings. Two distinct phases of nociceptive response are associated with the immediate activation of nociceptors and sensitization of spinal reflex circuits during phase I and II responses, respectively.⁵¹ Moreover, it has been recently suggested that formalin injection results in pathological changes that resemble those observed in nerve injury.⁵² The intraperitoneal (i.p.) administration of compound **7** prior to the subcutaneous injection of formalin significantly affected the duration of the nociceptive response in the acute phase of the formalin test ($F_{(4,40)} = 21.36$; $p < 0.0001$). This ligand also significantly attenuated the late phase of the test ($F_{(4,40)} = 16.50$; $p < 0.0001$). The calculated ED_{50} value in phase I was found to be 11.9 mg/kg, whereas the ED_{50} value in phase II was found to be 11.7 mg/kg (Figure 11b). The treatment with **3** resulted in a significant decrease in nociceptive response in both the acute phase ($F_{(3,34)} = 43.20$; $p < 0.0001$) and the late phase ($F_{(3,32)} = 17.63$; $p < 0.0001$). The potency of the compound expressed as the ED_{50} value was slightly lower than that obtained for the previous compound and was 14.21 and 13.31 mg/kg for the acute and late phases, respectively (Figure 11A). Ligand **12** showed high analgesic activity in the acute phase ($F_{(4,40)} = 13.73$; $p < 0.0001$) and late phase ($F_{(4,40)} = 9.51$; $p < 0.0001$) of the test (Figure 11C). Interestingly, the obtained ED_{50} values (6.17 and 12.32 mg/kg for the acute and late phase, respectively) reveal the particularly high potency of this compound in the acute, neurogenic phase, which suggests that it may affect the mechanisms of neurotransmitter release from neuronal cells.

Taking all data from preliminary studies, we decided to select compound **12** for further analysis of its analgesic activity. Although all three compounds showed significant activity in the formalin test, the safety profile of **12** was better than the other ligands. The chosen compound did not affect motor coordination significantly, and its ED_{50} value in the formalin test was almost two times lower than that obtained in the evaluation of the sedative activity. We used other models of pain to assess the range of analgesic activity of the compound with particular emphasis on neuropathic pain of different origins.

2.8.3. Effects of 12 on Capsaicin-Induced Nociception. Because compound **12** had a strong effect on the acute phase of the formalin test, we decided to evaluate its activity in capsaicin-induced pain, which is another model of neurogenic pain. Formalin-induced pain is mainly dependent on the chemical stimulation of the TRPA1 receptor on somatosensory nerve endings, whereas capsaicin is an agonist of TRPV1 receptors.⁵³

As shown in Figure 12, the selected compound significantly decreased the paw licking or biting behavior in that test at all administrated doses (10, 15, and 30 mg/kg) ($F_{(3,34)} = 28.48$, $p < 0.0001$). The ED_{50} value calculated for **12** in the capsaicin test was 10.32 mg/kg.

The high potency of **12** in both formalin- and capsaicin-induced pain shows that this compound has the potential to attenuate neurogenic pain independent of the mechanism of its induction. This suggests a broad spectrum of activity of this ligand.

2.8.4. Effects of 12 on Loperamide-Induced Antinociception. As it is well known that σ_1R antagonism enhances opioid analgesia, we tested the effects of compound **12** on antinociception induced by the opioid agonist loperamide.




Figure 11. Antinociceptive activity of 3 (A), 7 (B), and 12 (C) in the formalin test. Results are shown as time of licking in phase I (0–5 min after intraplantar injection of formalin) and in phase II (15–30 min after formalin injection). Each value represents the mean \pm S.E.M. for 8–10 animals. 0: vehicle (1% Tween 80). Statistical analysis: one-way ANOVA followed by *post hoc* Dunnett's test. Statistical significance compared to vehicle-treated animals: * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

SIRA was used as a σ_1 R reference antagonist and administered intraplantarly (i.pl.) at two doses of 50 and 100 μ g. Compound 12 was tested at 12.5 and 25 μ g. The antinociceptive effect of the treatments was tested in mice by monitoring the latency to struggle in response to a nociceptive mechanical stimulus applied to the paw. The subcutaneous (s.c.) administration of loperamide (4 mg/kg) induced a minimal (nonsignificant) increase in the struggle response latency in comparison to the values from mice treated with its solvent (Figure 13). The administration of SIRA alone (100 μ g) did not change the response to the mechanical stimulus but significantly and dose-dependently (50–100 μ g) increased the antinociceptive effect induced by loperamide and only in the paw injected with the σ_1 R antagonist (Figure 13). The administration of compound 12 (25 μ g) did not have any effect *per se* but dose-dependently




Figure 12. Antinociceptive activity of compound 12 in the capsaicin test. Results are shown as time of nociceptive response in 5 min period after intraplantar injection of capsaicin. Each value represents the mean \pm S.E.M. for 8–10 animals. Statistical analysis: one-way ANOVA followed by *post hoc* Dunnett's test. Statistical significance compared to vehicle-treated animals (Tween): **** p < 0.0001. 0: vehicle treated mice (1% Tween 80).

(12.5–25 μ g) increased the antinociceptive effect of loperamide at the injected paw, mirroring the effects induced by SIRA (Figure 13). Hence, the potency of compound 12 to enhance loperamide-induced antinociception was much higher than SIRA. Notably, the coadministration of the σ_1 R agonist PRE-084 (75 μ g) with SIRA, and also with 12, was able to markedly reverse the effect of these compounds on loperamide-induced antinociception (Figure 13). These data strongly support that not only SIRA but also compound 12 is a σ_1 receptor antagonists. Moreover, the effect of SIRA and 12 was also reversed by naloxone-methiodide that is a peripheral opioid antagonist. This means that the observed pharmacological effect is due to the peripheral potentiation of opioid antinociception by sigma-1 receptor antagonism.

In further studies, we used two different models of neuropathic pain to test the influence of 12 on pain associated with neuronal tissue damage: the oxaliplatin-induced model and the chronic constriction injury (CCI) model. The mechanism of neuron impairment is different in both, which may relate to the different efficacy of potential treatments. In the oxaliplatin-induced model, neurons are directly affected by this chemotherapeutic agent. That leads to mechanical allodynia resulting from the impaired regulation of ion channels and destruction of mitochondrial DNA, among others.⁵⁴ In CCI, neuropathy impairs peripheral nerve function, and neuronal damage results from a persistent mechanical stimulus and its complications such as vascular and metabolic dysfunctions.

2.8.5. Oxaliplatin (OXPT)-Induced Neuropathy. The neuropathy manifests as a decrease in the pain threshold and can be observed in hours or in days after oxaliplatin administration, which is called the early or late phase of neuropathic pain, respectively. We tested the influence of compound 12 on tactile allodynia using the von Frey method 3 h and 7 days after the induction of neuropathy.¹²

In the group treated with 12 at the dose of 5 mg/kg (Figure 14), the initial value of 5.53 ± 0.34 (baseline) was decreased to the value of 3.51 ± 0.17 (63.5% of the baseline) and 4.30 ± 0.08 (77.7% of the baseline) in the early and late phase, respectively. The single administration of 12 partially reversed the effect of OXPT in the early phase (88.6% of the baseline; $F_{(2,136, 19,22)} = 7.66$, p < 0.01) but not in the late phase. In the group treated with 12 at the dose of 10 mg/kg, the initial value of 5.83 ± 0.41 was decreased to the value of 2.94 ± 0.36




Figure 13. Effects of S1RA and 12 on loperamide-induced antinociception. The results represent the struggle response latency during stimulation with 450 g pressure in mice intraplantarly (i.pl.) administered S1RA (50–100 μg), 12 (12.5–25 μg), or saline and treated subcutaneously (s.c.) with loperamide (4 mg/kg) or its solvent (1% DMSO in ultrapure water). (A) Effect of treatments on the response latency to mechanical stimulation in the paw i.pl. injected with the σ_1 R ligands (ipsi) and in the contralateral paw (contra). (B) Effect of the i.pl. administration of PRE-084 (75 μg) and the s.c. administration of naloxone-methiodide (NxM, 2 mg/kg) on the potentiation of loperamide-induced antinociception by S1RA and 12. Each bar and vertical line represent the mean \pm SEM of values obtained in six to eight animals. Two-way analysis of variance followed by the Bonferroni test was used to determine statistically significant differences (A and B) between the values obtained in the group treated with the solvent of the drugs and the rest of the groups (* p < 0.05, ** p < 0.01), (A) between the ipsi and the contra paws (### p < 0.01), and (B) between the values of the ipsi paw from loperamide-treated mice injected with S1RA or 12 alone and coadministered with PRE-084 or with the association with NxM (†† p < 0.01).




Figure 14. Antiallodynic effects of compound 12 in the tactile allodynia evaluated in the von Frey test in oxaliplatin-induced peripheral neuropathy. Each experimental group consisted of 8–10 animals. ** p < 0.01, *** p < 0.001, and **** p < 0.0001 (repeated measures analysis of variance (ANOVA) followed by Dunnett's *post hoc* test) when the groups were compared to oxaliplatin treatment; ^ p < 0.05, ^^ p < 0.01, and ^^ p < 0.001 (repeated measures analysis of variance ANOVA followed by *post hoc* Dunnett's test) when the groups were compared to naive animals.

(50.4% of the baseline) and 3.94 ± 0.36 (67.6% of the baseline) in the early and the late phase, respectively. The single administration of 12 reversed the effect of OXPT in both the early phase (115.0% of the baseline) and the late phase (99.8% of the baseline) ($F_{(2,574, 20.59)} = 17.84$, p < 0.0001). In the group treated with 12 at the dose of 15 mg/kg, the initial value of 5.60 ± 0.33 was decreased to the value of 3.73 ± 0.38 (66.6% of the baseline) and 3.88 ± 0.27 (69.3% of the baseline) in the early and late phase, respectively. The single administration of 12 completely reversed the effect of OXPT and even elevated the pain threshold above the baseline in both the early phase (124.3% of the baseline) and the late phase (123.7% of the baseline) ($F_{(2,317, 41.71)} = 21.67$, p < 0.0001).

These results indicate that compound 12 exhibits potency for relieving chemotherapy-induced neuropathic pain (all the tested doses were significantly active), which confirms its wide range of analgesic activity and encourages further research.

2.8.6. Effects of 12 on Neuropathic Pain Symptoms in CCI-Exposed Mice. Behavioral assessment of 12 was performed 14 days after the sciatic nerve injury. Mice were randomly

assigned to four treatment groups: vehicle-treated (i.p.) and 12-treated (5, 10, and 15 mg/kg, i.p.). Baseline measurements (basal) for all tests were performed before compound injections, and the results are presented as percentages of the maximal possible effect (% MPE). We observed a significant effect of the tested compound in the von Frey test at all tested time points (30 min: $F_{(3, 26)} = 12.38$, p < 0.0001; 90 min: $F_{(3, 26)} = 12.65$, p < 0.0001; 180 min: $F_{(3, 26)} = 6.464$, p = 0.0020). In CCI-exposed mice, 12 exhibited significant analgesic effects 30 min after injection of 5 (p < 0.0001) and 10 mg/kg (p = 0.0201) in the von Frey test compared with vehicle-treated animals (Figure 15A). However, a single injection of compound 12 only at a dose of 10 mg/kg increased the withdrawal thresholds in the von Frey test at 90 (p < 0.0001) and 180 (p = 0.0014) min after administration (Figure 15A). We also observed a significant effect of treatment on the contralateral paw 90 min after injection ($F_{(3, 26)} = 5.741$, p = 0.0037). Further analysis showed no effects of compound 12 (for doses 5 and 10 mg/kg) on tactile allodynia in the von Frey test at all time points after treatment. However, 12 at dose 15 mg/kg reduced the withdrawal




Figure 15. The effects of single i.p. administration of **12** (5, 10 and 15 mg/kg) on mechanical (A, von Frey test) and thermal (B, cold plate test; C, tail flick test) stimulus on day 14 following CCI to the sciatic nerve were evaluated ($n = 7-8$ animals per group). The results are presented as percentages of the maximal possible effect (% MPE; means \pm SEM). Intergroup differences were analyzed by one-way ANOVA with Bonferroni's multiple comparison *post hoc* test. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ vs vehicle-treated group.

threshold 30 and 180 min after injection, although this effect was not statistically significant at those time points. But 90 min after injection, we observed a significant effect ($p = 0.0056$) (Figure S33). We have also observed a significant effect of treatment on thermal stimuli as measured in a cold plate test at all tested time points (35 min: $F_{(3, 26)} = 20.77$, $p < 0.0001$; 95 min: $F_{(3, 26)} = 32.42$, $p < 0.0001$; 185 min: $F_{(3, 26)} = 16.11$, $p < 0.0001$). Here, analgesic effects of **12** single injection were observed at 35 min for all tested doses as compared with control animals (5 mg/kg: $p = 0.019$; 10 mg/kg: $p < 0.0001$; 15 mg/kg: $p = 0.0004$) (Figure 15B). This antihyperalgesic

effect was also observed 95 min after injection (5 mg/kg: $p = 0.0072$; 10 mg/kg: $p < 0.0001$; 15 mg/kg: $p = 0.0002$) (Figure 15B). However, 185 min after treatment, the analgesic effect was significant only for doses 5 ($p = 0.0482$) and 10 mg/kg ($p < 0.0001$). The measurements of spinal responses assessed by the tail flick test also revealed a significant effect of treatments (40 min: $F_{(3, 25)} = 11.74$, $p < 0.0001$; 100 min: $F_{(3, 25)} = 35.93$, $p < 0.0001$; 190 min: $F_{(3, 25)} = 7.479$, $p = 0.001$). The analysis of the tail flick test results (Figure 15C) showed significant analgesic action of **12** at 40 min (for doses 5 ($p = 0.021$) and 10 mg/kg ($p < 0.0001$)) after injection as compared with

vehicle-treated mice. At the further time points (100 and 190 min), only the 10 mg/kg dose had significant analgesic effects ($p < 0.0001$ and $p = 0.0033$, respectively) (Figure 15C).

3. CONCLUSIONS

Comprehensive and rational drug discovery requires a multidisciplinary approach involving many techniques and methods. A deeper understanding of the molecule's physicochemical properties and its conformational preferences may be very helpful, especially in the case of selective or dual (multi)-target therapeutic agent design.

In our study, we decided to combine chemical, biological, and computational methods to reveal molecular properties responsible for histamine H_3R and σ_1R selective or dual-target binding of the studied compounds. Considering the different abilities of piperidine and piperazine derivatives substituted with a 4-pyridyl moiety to form a salt bridge with Glu172 in the σ_1R binding pocket, which is a crucial interaction for ligand–protein complex stability and thus the high biological activity, we performed an in-depth analysis of their protonation states with three different methods. In the case of piperidine derivatives, the crystal structure confirmed the presence of two protonation centers with higher basic properties of the piperidine vs pyridine nitrogen atom. In contrast, for the piperazine derivatives, we observed a strong basic character of the pyridine nitrogen atom as a consequence of the increased availability of the lone pair electrons. The former is correlated with the source of electrons located at the para position, originated in the piperazine ring's nitrogen atom with its lone pair of electrons being involved in the π -electron resonance. The observed rigidity of the 4-pyridylpiperazine fragment not only determines the highly basic character of pyridine nitrogen atom but also strongly defines the spatial orientation of π -electrons of the aromatic fragment. This geometrical feature is most likely responsible for the effective ligand–protein recognition and may explain the observed selectivity of the investigated compounds containing 4-pyridylpiperazine fragment for H_3R . Moreover, the order of protonation of individual nitrogen atoms based on NMR spectroscopy measurements in a pH-controlled environment stays in agreement with the crystallographic data for both piperidines and piperazines. Interestingly, for the piperazine derivative **KSK94**, we observed a transfer of the positive charge from the pyridine nitrogen atom, which was protonated first, to the piperazine nitrogen through appropriate resonance structures. This observation is fully consistent with the crystallographic data and explains the inability of 4-pyridylpiperazine derivatives to form a salt bridge with Glu172 in the σ_1R binding pocket. This is caused by the low basicity of the second piperazine nitrogen atom, which was initially unprotonated. A series of titrations allowed determining pK_a values of individual nitrogen atoms and recognizing piperidine derivative **KSK68** as a basic ligand with $pK_{a1} = 4.9$ (pyridine N) and $pK_{a2} = 8.4$ (piperidine N). In turn, the **KSK94** compound belongs to ligands with an acidic center located on the piperazine nitrogen atom to which the pyridine ring is directly attached ($pK_{a2} = 1$). The protonation states of the compounds were also assessed *in silico*, and the obtained results were consistent with the experimental data.

In the next step, we designed and synthesized a series of 16 novel compounds, mainly piperidine derivatives, and determined their affinity at H_3R , σ_1R , and σ_2R . We confirmed the previously described phenomenon and identified a second pair

of similar compounds, differing only in the 4-pyridylpiperazine/piperidine core with dual H_3/σ_1R activity of the piperidine derivative **12** and no affinity toward σ_1R of its piperazine analogue **KSK94**. To further investigate the impact of structural differences between these moieties on their molecular mode of action, the binding to σ_1R and H_3R was evaluated using molecular modeling techniques and molecular dynamics simulations. Both the free binding energies and the docking scores of the most abundant protonation states correlated with the *in vitro* activity of the tested ligands.

As the lead structures for further evaluation, we selected compounds **3** and **7** with the highest σ_2/σ_1 selectivity factor (13.2 and 24.2, respectively) and ligand **12** with the same high σ_2R activity as for major biological targets. It is well known that sigma receptors modulate nociception, offering a potential therapeutic target for pain management, but relatively little is known about the role of σ_2R in the pathomechanism of this condition. Interestingly, recent studies with the highly σ_2R -selective compound CM-398 showed that it ameliorates inflammatory and chronic neuropathic pain in established mouse models, suggesting possible mediation of nociception by σ_2R .³³ Therefore, it seems reasonable to test triple-targeting $H_3/\sigma_1/\sigma_2R$ ligand **12** alongside the dual-acting compounds **3** and **7**.

All lead structures had no affinity at other histamine receptor subtypes and were characterized as potent H_3R antagonists in the cAMP accumulation assay. Moreover, we checked their ability to penetrate lipid membranes by parallel artificial membrane permeability assay. All tested molecules can be considered substances with high passive transport through biological membranes. Taking into account an intracellular localization of σ_1R , the satisfactory level of lipid membranes penetration and thus the ability of studied compounds to reach this biological target seem to be an important feature of dual H_3/σ_1R ligands. Furthermore, we also tested the serum stability of compound **12**, and the obtained data clearly indicate that it can be considered as a moderately stable ligand, which is relatively rapidly degraded by serum enzymes. This is associated with the presence of a hydrolysis-susceptible nitrile group within its structure. On the other hand, this moiety was one of the key structural element responsible for the pharmacological activity of **12**. Thus, the identification of other groups in this region, less sensitive to serum enzymes activity, will be the subject of our further studies. Knowledge of the permeability profile and stability in plasma of tested ligand is a very preliminary step in predicting its exposure required for *in vivo* efficacy.

Finally, we tested the efficacy of compounds **3**, **7**, and **12** in animal models of pain. We started by testing the safety pharmacology and checked their influence on spontaneous locomotor activity and motor coordination in the rotarod test. Compounds **3** and **7** showed high and significant sedative effects and significantly impaired motor coordination in mice at the administrated doses. In contrast, the obtained results showed that **12** is characterized by a better safety profile than the other two tested compounds; hence, we chose this ligand for further analysis of its analgesic activity. The high potency of **12** in both formalin- and capsaicin-induced pain shows that this compound has the potential to attenuate neurogenic pain regardless of the mechanism of its induction. We then tested the effect of **12** on antinociception induced by the opioid agonist loperamide. Administration of compound **12** enhanced the effect of loperamide, which was markedly reversed by co-

administration of the σ_1 R agonist PRE-084. These data strongly support that **12** is a potent σ_1 R antagonist. Finally, we used two different models of neuropathic pain to test the influence of **12** on pain associated with neuronal tissue damage. The obtained results indicate that compound **12** has the potential to alleviate both chemotherapy-induced neuropathic pain and pain resulting from sciatic nerve damage. This confirms its broad spectrum of analgesic activity, which may be related to the dual H_3/σ_1 R modulation as well as the additional interaction with σ_2 R. Determining the exact mechanism of action of compound **12** will be the subject of our further studies.

4. EXPERIMENTAL PROTOCOLS

4.1. Chemistry. All reagents were purchased from commercial suppliers and were used without further purification. Melting points (m.p.) were determined on a MEL-TEMP melting point apparatus II (LD Inc., USA) and are uncorrected. HPLC analysis was performed on an Agilent 1290 UHPLC system coupled with an Agilent QTOF 6545 mass spectrometer (a Phenomenex Kinetex 1.7 μ m EVO C18 (100 Å, 50 × 2.1 mm) reversed-phase column was used). Mass spectra (LC/MS) were carried out on a system consisting of a Waters Acquity UPLC coupled to a Waters TQD mass spectrometer. Retention times (t_R) are given in minutes. High-resolution mass spectrometry (HRMS) was performed on Thermo Scientific Orbitrap Exploris 240 mass spectrometer. 1 H NMR spectra were recorded on a Varian Mercury 300 MHz PFG spectrometer in DMSO- d_6 . Chemical shifts were expressed in parts per million (ppm) using the solvent signal as an internal standard. Data are reported in the following order: multiplicity (s, singlet; d, doublet; dd, double of doublets; t, triplet; tt, triplet of triplets; quin, quintet; qd, quartet of doublets; m, multiplet; br, broad), approximate coupling constants J expressed in hertz (Hz), and number of protons. 13 C NMR spectra were recorded on a Varian-Mercury-VX 300 MHz PFG or Bruker 400 MHz spectrometer at 75 MHz in DMSO- d_6 . Elemental analyses (C, H, N) were performed on a Vario El III elemental analyzer (Hanau, Germany). For CC purification (column chromatography using silica gel 60 (0.063–0.20 mm); Merck), the following solvent systems were used: I: petroleum ether/EtOAc (9:1); II: CH_2Cl_2 /MeOH (9:1). Chemical compounds' names were generated using Chem Draw Professional 18.0.0.231 (4029).

All final compounds are >95% pure by HPLC analysis.

4.1.1. General Synthetic Procedure for Compounds a–i. All compounds were obtained using methods described previously.^{19,21,22,24,25} To a solution of freshly prepared sodium 1-propanolate (0.1 mol, 100 mL), proper substituted phenols (0.1 mol) were added and stirred in room temperature for 5 min. α,ω -Dibromoalkanes (0.2 mol) were then added dropwise in the time of 1 h. The reaction mixture was stirred in 60 °C for 3 h and then refluxed for another 3 h. After cooling down to RT, the mixture was filtrated and evaporated. To a rough product, 100 mL of 10% NaOH was added and left overnight in the cold. To a resulting white oil, CH_2Cl_2 was added and mixed, and layers were then separated. The organic layer was dried over sodium sulfate, filtered, and evaporated. The rough product was used for further reactions after purification.

4.1.1.1. 4-(3-Bromopropoxy)-1,1'-biphenyl (a). Compound previously described in the literature.²¹ Obtained 22.13 g of raw product, purified by CC (I), yield 76%. CAS113795-28-1.

4.1.1.2. 4'-(3-Bromopropoxy)-[1,1'-biphenyl]-4-carbonitrile (b). Compound previously described in the literature.²² Obtained 17.71 g of raw product, purified by CC (I), yield 56%. CAS134880-32-3.

4.1.1.3. 1-(3-Bromopropoxy)-4-phenoxybenzene (c). Compound previously described in the literature.²² Obtained 16.59 g of raw product, purified by CC (I), yield 54%. CAS63457-51-2.

4.1.1.4. 4-(3-Bromopropoxy)-N-phenylaniline (d). Compound previously described in the literature.²² Obtained 15.92 g of raw product, purified by CC (I), yield 52%.

4.1.1.5. 1-Benzyl-4-(3-bromopropoxy)benzene (e). Compound previously described in the literature.²² Obtained 17.40 g of raw product, purified by CC (I), yield 57%. CAS60859-24-7.

4.1.1.6. 4-(4-Bromobutoxy)-1,1'-biphenyl (f). Compound previously described in the literature.⁵⁵ Obtained 12.51 g of raw product, purified by CC (I), yield 41%. CAS53669-78-6.

4.1.1.7. 4-((5-Bromopentyl)oxy)-1,1'-biphenyl (g). Compound previously described in the literature.²⁴ Obtained 7.66 g of raw product, purified by CC (I), yield 24%. CAS52273-19-5.

4.1.1.8. 4-((6-Bromohexyl)oxy)-1,1'-biphenyl (h). Compound previously described in the literature.²⁴ Obtained 8.33 g of raw product, purified by CC (I), yield 25%. CAS158136-46-0.

4.1.1.9. 1-(4-Bromobutoxy)-4-(tert-butyl)benzene (i). Compound previously described in the literature.¹⁹ Obtained 19.68 g of raw product, purified by CC (I), yield 69%. CAS53669-73-1.

4.1.2. General Synthetic Procedure for Compounds 1–16. All compounds were obtained using methods described previously.^{19,21,22,24,25} To a suspension of potassium carbonate (8.5 mmol) and a catalytic amount of potassium iodide in water (10 mL), a mixture of proper amine (5 mmol) and compound a–i (5 mmol) in ethanol (50 mL) was added as previously described.^{19,21,22,24,25} The mixture was then refluxed for 8–12 h (TLC controlled). After cooling down to room temperature, reaction mixture was filtrated, evaporated, and purified. To the resulting oil, 100 mL of CH_2Cl_2 was added and washed with 0.5% HCl solution, 0.5% NaOH solution, and water. After drying over anhydrous Na_2SO_4 and evaporation of the organic layer, the product was further purified using CC (II). Compounds **5**, **10**, **11**, and **16** were obtained as in previous studies and used in the biological assays with high purity estimated using LC/MS; details of their synthesis and analyses are described elsewhere.^{19,24,25}

4.1.2.1. 1-(3-([1,1'-Biphenyl]-4-yloxy)propyl)-3-methylpiperidine Oxalate (1). White solid, yield 30%, m.p. 169–172 °C, $C_{21}H_{27}NO \cdot C_2H_2O_4$ (MW = 399.49). RP-HPLC: 99.67% (t_R = 2.890, k' = 14.21). 1 H NMR (500 MHz, DMSO- d_6) δ ppm: 7.57 (dd, J = 2.00, 8.31 Hz, 4H), 7.39 (t, J = 7.73 Hz, 2H), 7.24–7.31 (m, 1H), 6.99 (d, J = 8.59 Hz, 2H), 4.04 (t, J = 6.01 Hz, 2H), 3.28–3.42 (m, 2H), 3.10 (t, J = 7.59 Hz, 2H), 2.71 (t, J = 10.74 Hz, 1H), 2.43 (br. s., 1H), 2.11 (quin, J = 6.80 Hz, 2H), 1.79–1.90 (m, 1H), 1.62–1.78 (m, 3H), 0.95–1.09 (m, 1H), 0.86 (d, J = 6.59 Hz, 3H). 13 C NMR (126 MHz, DMSO- d_6) δ ppm: 165.2, 158.4, 140.3, 133.3, 129.4, 128.3, 127.3, 126.7, 115.5, 65.7, 58.1, 54.0, 52.2, 30.6, 29.1, 24.1, 22.8, 22.8, 19.1. LC–MS: purity 100.00%, t_R = 5.53, (ESI) m/z [M + H]⁺ 310.22. Anal. calcd. for $C_{23}H_{29}NO_5$: C, 69.15; H, 7.32; N, 3.51%. Found: C, 68.94; H, 7.08; N, 3.46%.

4.1.2.2. 1-(3-([1,1'-Biphenyl]-4-yloxy)propyl)-4-methylpiperidine Oxalate (2). White solid, yield 38%, m.p. 222–224 °C, $C_{21}H_{27}NO \cdot C_2H_2O_4$ (MW = 399.49). RP-HPLC: 97.96% (t_R = 2.888, k' = 14.20). 1 H NMR (500 MHz, DMSO- d_6) δ ppm: 7.57 (d, J = 8.59 Hz, 4H), 7.39 (t, J = 7.73 Hz, 2H), 7.24–7.30 (m, 1H), 6.99 (d, J = 8.59 Hz, 2H), 4.05 (t, J = 6.01 Hz, 2H), 3.37 (d, J = 10.60 Hz, 2H), 3.06–3.15 (m, 2H), 2.83 (br. s., 2H), 2.02–2.15 (m, 2H), 1.74 (d, J = 13.46 Hz, 2H), 1.57 (br. s., 1H), 1.27–1.40 (m, 2H), 0.89 (d, J = 6.30 Hz, 3H). 13 C NMR (126 MHz, DMSO- d_6) δ ppm: 140.28, 133.34, 129.42, 128.32, 126.71, 115.48, 100.00, 65.60, 24.28. LC–MS: purity 97.76%, t_R = 5.47, (ESI) m/z [M + H]⁺ 310.22. Anal. calcd. for $C_{23}H_{29}NO_5$: C, 69.15; H, 7.32; N, 3.51%. Found: C, 68.82; H, 7.53; N, 3.38%.

4.1.2.3. 1-(3-([1,1'-Biphenyl]-4-yloxy)propyl)azepane Oxalate (3). White solid, yield 38%, m.p. 187–190 °C, $C_{21}H_{27}NO \cdot C_2H_2O_4$ (MW = 399.49). RP-HPLC: 96.06% (t_R = 2.875, k' = 14.13). 1 H NMR (500 MHz, DMSO- d_6) δ ppm: 7.57 (d, J = 7.73 Hz, 4H), 7.39 (t, J = 7.30 Hz, 2H), 7.27 (t, J = 7.16 Hz, 1H), 7.00 (d, J = 8.31 Hz, 2H), 4.05 (t, J = 5.58 Hz, 2H), 2.93–3.40 (m, 6H), 2.10 (br. s., 2H), 1.76 (br. s., 4H), 1.40–1.63 (m, 4H). 13 C NMR (126 MHz, DMSO- d_6) δ ppm: 165.1, 158.4, 140.3, 133.3, 129.4, 128.3, 127.3, 126.7, 115.5, 65.6, 54.3, 54.2, 26.5, 24.5, 23.7. LC–MS: purity 96.08%, t_R = 5.51, (ESI) m/z [M + H]⁺ 310.22. Anal. calcd. for $C_{23}H_{29}NO_5$: C, 69.15; H, 7.32; N, 3.51%. Found: C, 68.71; H, 7.08; N, 3.38%.

4.1.2.4. 1-(3-([1,1'-Biphenyl]-4-yloxy)propyl)pyrrolidine Oxalate (4). White solid, yield 42%, m.p. 204–206 °C, $C_{19}H_{23}NO \cdot C_2H_2O_4$

(MW = 371.43). RP-HPLC: 96.58% ($t_R = 2.768$, $k' = 13.57$). ^1H NMR (500 MHz, DMSO- d_6) δ ppm: 7.57 (d, $J = 8.31$ Hz, 4H), 7.39 (t, $J = 7.59$ Hz, 2H), 7.23–7.31 (m, 1H), 6.99 (d, $J = 8.59$ Hz, 2H), 4.05 (t, $J = 5.87$ Hz, 2H), 3.01–3.42 (m, 6H), 2.03–2.13 (m, 2H), 1.89 (br. s., 4H). ^{13}C NMR (126 MHz, DMSO- d_6) δ ppm: 165.0, 158.4, 140.3, 133.3, 129.4, 128.3, 127.3, 126.7, 115.6, 115.5, 65.4, 53.7, 51.9, 25.9, 23.2. LC–MS: purity 100.00%, $t_R = 5.10$ (ESI) m/z $[M + H]^+$ 282.137. HRMS (MALDI): m/z $[M + H]^+$ 282.1856.

4.1.2.5. 4'-(3-(Piperidin-1-yl)propoxy)-[1,1'-biphenyl]-4-carbonitrile Oxalate (5). Compound previously described in the literature.²⁵ White solid, yield 37%. RP-HPLC: 95.63% ($t_R = 2.731$, $k' = 13.37$). LC–MS: purity 93.82%, $t_R = 4.64$, (ESI) m/z $[M + H]^+$ 321.26. HRMS (MALDI): m/z $[M + H]^+$ 321.1966.

4.1.2.6. 1-(3-(4-Phenoxyphenoxy)propyl)piperidine Oxalate (6). White solid, yield 46%, m.p. 137–140 °C, C₂₀H₂₅N₃O₂·C₂H₂O₄ (MW = 401.46). RP-HPLC: 100.00% ($t_R = 2.808$, $k' = 13.78$). ^1H NMR (500 MHz, DMSO- d_6) δ ppm: 7.26–7.36 (m, 2H), 7.03 (t, $J = 7.30$ Hz, 1H), 6.90–6.98 (m, 4H), 6.87 (d, $J = 7.73$ Hz, 2H), 3.98 (t, $J = 6.01$ Hz, 2H), 2.79–3.36 (m, 6H), 2.00–2.16 (m, 2H), 1.60–1.77 (m, 4H), 1.49 (br. s., 2H). ^{13}C NMR (126 MHz, DMSO- d_6) δ ppm: 165.3, 158.5, 155.2, 150.1, 130.4, 123.2, 121.2, 117.9, 116.3, 66.0, 54.0, 52.6, 24.1, 23.1, 22.0. LC–MS: purity 97.09%, $t_R = 5.19$, (ESI) m/z $[M + H]^+$ 312.41. Anal. calcd. for C₂₂H₂₇N₃O₆: C, 65.82; H, 6.78; N, 3.49%. Found: C, 65.59; H, 6.61; N, 3.39%.

4.1.2.7. N-Phenyl-4-(3-(piperidin-1-yl)propoxy)aniline Oxalate (7). White solid, yield 34%, m.p. 130–133 °C, C₂₀H₂₆N₂O·C₂H₂O₄ (MW = 400.48). RP-HPLC: 99.41% ($t_R = 2.726$, $k' = 13.35$). ^1H NMR (400 MHz, DMSO- d_6) δ ppm: 7.87 (br. s., 1H), 7.12–7.22 (m, 2H), 7.04 (d, $J = 9.00$ Hz, 2H), 6.83–6.96 (m, 4H), 6.72 (t, $J = 7.24$ Hz, 1H), 3.98 (t, $J = 5.87$ Hz, 2H), 2.91–3.32 (m, 6H), 2.04–2.20 (m, 2H), 1.63–1.84 (m, 4H), 1.53 (br. s., 2H). ^{13}C NMR (101 MHz, DMSO- d_6) δ ppm: 165.1, 153.1, 145.4, 136.9, 129.6, 120.6, 118.8, 115.8, 115.4, 65.8, 54.1, 52.6, 24.1, 23.2, 22.0. LC–MS: purity 100%, $t_R = 4.88$, (ESI) m/z $[M + H]^+$ 311.41. Anal. calcd. for C₂₂H₂₈N₂O₅: C, 65.98; H, 7.05; N, 7.00%. Found: C, 66.25; H, 6.89; N, 7.00%.

4.1.2.8. 1-(3-(4-Benzylphenoxy)propyl)piperidine Oxalate (8). White solid, yield 39%, m.p. 152–155 °C, C₂₁H₂₉N₃O·C₂H₂O₄ (MW = 399.49). RP-HPLC: 98.02% ($t_R = 2.866$, $k' = 14.08$). ^1H NMR (500 MHz, DMSO- d_6) δ ppm: 7.19–7.29 (m, 2H), 7.03–7.18 (m, 5H), 6.81 (d, $J = 8.59$ Hz, 2H), 3.94 (t, $J = 6.01$ Hz, 2H), 3.82 (s, 2H), 2.76–3.43 (m, 6H), 1.98–2.11 (m, 2H), 1.62–1.75 (m, 4H), 1.47 (br. s., 2H). ^{13}C NMR (126 MHz, DMSO- d_6) δ ppm: 165.3, 157.1, 142.3, 134.1, 130.2, 129.1, 128.9, 126.4, 115.0, 65.5, 54.0, 52.6, 24.0, 23.1, 22.0. LC–MS: purity 100.00%, $t_R = 5.35$, (ESI) m/z $[M + H]^+$ 310.47. Anal. calcd. for C₂₃H₂₉N₃O₅: C, 69.15; H, 7.32; N, 3.51%. Found: C, 68.46; H, 7.53; N, 3.36%.

4.1.2.9. 1-(4-([1,1'-Biphenyl]-4-yloxy)butyl)piperidine Oxalate (9). White solid, yield 24%, m.p. 182–185 °C, C₂₁H₂₇N₃O·C₂H₂O₄ (MW = 399.49). RP-HPLC: 97.54% ($t_R = 2.863$, $k' = 14.07$). ^1H NMR (500 MHz, DMSO- d_6) δ ppm: 7.56 (dd, $J = 5.58$, 7.59 Hz, 4H), 7.39 (t, $J = 7.73$ Hz, 2H), 7.18–7.31 (m, 1H), 6.88–7.06 (m, 2H), 4.00 (t, $J = 5.87$ Hz, 2H), 2.72–3.49 (m, 6H), 1.58–1.86 (m, 8H), 1.29–1.58 (m, 2H). ^{13}C NMR (126 MHz, DMSO- d_6) δ ppm: 165.1, 165.1, 165.0, 158.7, 140.3, 133.1, 129.4, 128.3, 127.3, 126.7, 115.5, 67.4, 56.1, 52.5, 26.5, 23.1, 22.0, 20.8. LC–MS: purity 96.17%, $t_R = 5.46$, (ESI) m/z $[M + H]^+$ 310.22. Anal. calcd. for C₂₃H₂₉N₃O₅: C, 69.15; H, 7.32; N, 3.51%. Found: C, 68.78; H, 7.47; N, 3.31%.

4.1.2.10. 1-(5-([1,1'-Biphenyl]-4-yloxy)pentyl)piperidine Oxalate (10). Compound previously described in the literature.²⁴ White solid, yield 66%. RP-HPLC: 98.88% ($t_R = 2.934$, $k' = 14.44$). LC–MS: purity 99.60%, $t_R = 5.81$, (ESI) m/z $[M + H]^+$ 324.44.

4.1.2.11. 1-(6-([1,1'-Biphenyl]-4-yloxy)hexyl)piperidine Oxalate (11). Compound previously described in the literature.²⁴ White solid, yield 60%. RP-HPLC: 100.00% ($t_R = 3.013$, $k' = 14.86$). LC–MS: purity 100.00%, $t_R = 6.18$, (ESI) m/z $[M + H]^+$ 338.47.

4.1.2.12. 4'-(3-(4-(Pyridin-4-yl)piperidin-1-yl)propoxy)-[1,1'-biphenyl]-4-carbonitrile Oxalate (12). White solid, yield 32%, m.p. 157–160 °C, C₂₆H₂₇N₃O·C₂H₂O₄ (MW = 487.56). RP-HPLC: 100.00% ($t_R = 2.431$, $k' = 11.79$). ^1H NMR (500 MHz, DMSO- d_6) δ ppm: 8.40–8.43 (m, 2H), 7.79–7.86 (m, 4H), 7.65–7.69 (m, 2H),

7.22–7.24 (m, 2H), 7.01–7.04 (m, 2H), 4.04 (t, $J = 6.44$ Hz, 2H), 2.95 (d, $J = 11.46$ Hz, 2H), 2.48–2.52 (m, 1H), 2.43 (t, $J = 7.16$ Hz, 2H), 1.93–2.01 (m, 2H), 1.88 (quin, $J = 6.73$ Hz, 2H), 1.69–1.76 (m, 2H), 1.55–1.65 (m, 2H). ^{13}C NMR (126 MHz, DMSO- d_6) δ ppm: 159.9, 155.3, 150.1, 144.8, 133.3, 128.9, 127.4, 122.9, 115.7, 109.6, 66.6, 55.2, 54.1, 32.6, 26.9. LC–MS: purity 100.00%, $t_R = 3.54$, (ESI) m/z $[M + H]^+$ 398.12. HRMS (MALDI): m/z $[M + H]^+$ 398.2230.

4.1.2.13. 4-(1-(3-(4-Phenoxyphenoxy)propyl)piperidin-4-yl)pyridine Oxalate (13). White solid, yield 34%, m.p. 143–146 °C, C₂₅H₂₈N₂O₂·C₂H₂O₄ (MW = 478.55). RP-HPLC: 100.00% ($t_R = 2.492$, $k' = 12.12$). ^1H NMR (500 MHz, DMSO- d_6) δ ppm: 8.41–8.43 (m, 2H), 7.28–7.32 (m, 2H), 7.22–7.25 (m, 2H), 7.02 (t, $J = 7.41$, 1.04 Hz, 1H), 6.90–6.96 (m, 4H), 6.86–6.89 (m, 2H), 3.96 (t, $J = 6.30$ Hz, 2H), 2.95 (d, $J = 11.46$ Hz, 2H), 2.48–2.52 (m, 1H), 2.42 (t, $J = 7.30$ Hz, 2H), 1.93–2.00 (m, 2H), 1.82–1.89 (m, 2H), 1.72 (d, $J = 12.60$ Hz, 2H), 1.60 (qd, $J = 12.36$, 3.58 Hz, 2H). ^{13}C NMR (126 MHz, DMSO- d_6) δ ppm: 158.6, 155.6, 149.8, 130.4, 122.9, 117.8, 116.2, 66.8, 55.2, 54.1, 32.6, 27.0. LC–MS: purity 100.00%, $t_R = 3.94$, (ESI) m/z $[M + H]^+$ 389.23. HRMS (MALDI): m/z $[M + H]^+$ 389.2227.

4.1.2.14. N-Phenyl-4-(3-(4-(pyridin-4-yl)piperidin-1-yl)propoxy)aniline Oxalate (14). White solid, yield 38%, m.p. 182–185 °C, C₂₅H₂₉N₃O·C₂H₂O₄ (MW = 477.56). RP-HPLC: 100.00% ($t_R = 2.400$, $k' = 11.63$). ^1H NMR (500 MHz, DMSO- d_6) δ ppm: 8.41–8.43 (m, 2H), 7.80 (s, 1H), 7.22–7.24 (m, 2H), 7.09–7.13 (m, 2H), 6.97–7.01 (m, 2H), 6.86–6.89 (m, 2H), 6.80–6.84 (m, 2H), 6.66 (tt, $J = 7.30$, 1.15 Hz, 1H), 3.92 (t, $J = 6.30$ Hz, 2H), 2.97 (d, $J = 10.02$ Hz, 2H), 2.48–2.54 (m, 2H), 2.00 (br. s., 2H), 1.84 (quin, $J = 6.73$ Hz, 2H), 1.73 (d, $J = 12.03$ Hz, 2H), 1.61 (qd, $J = 12.32$, 3.44 Hz, 2H). ^{13}C NMR (126 MHz, DMSO- d_6) δ ppm: 155.3, 153.6, 150.1, 145.6, 136.6, 129.6, 122.9, 120.8, 118.8, 115.7, 115.3, 66.6, 55.3, 54.0, 32.5, 26.9. LC–MS: purity 100.00%, $t_R = 3.62$, (ESI) m/z $[M + H]^+$ 388. HRMS (MALDI): m/z $[M + H]^+$ 388.2387.

4.1.2.15. 4-(1-(3-(4-Benzylphenoxy)propyl)piperidin-4-yl)pyridine Oxalate (15). White solid, yield 41%, m.p. 135–138 °C, C₂₆H₃₀N₂O·C₂H₂O₄ (MW = 476.57). RP-HPLC: 98.95% ($t_R = 2.538$, $k' = 12.36$). ^1H NMR (500 MHz, DMSO- d_6) δ ppm: 8.40–8.43 (m, 2H), 7.21–7.25 (m, 4H), 7.06–7.17 (m, 5H), 6.78–6.82 (m, 2H), 3.92 (t, $J = 6.44$ Hz, 2H), 3.82 (s, 2H), 3.29 (br. s., 1H), 2.94 (d, $J = 10.88$ Hz, 2H), 2.37–2.44 (m, 2H), 1.90–2.04 (m, 2H), 1.83 (quin, $J = 6.80$ Hz, 2H), 1.71 (d, $J = 12.03$ Hz, 2H), 1.59 (qd, $J = 12.32$, 3.72 Hz, 2H). ^{13}C NMR (126 MHz, DMSO- d_6) δ ppm: 157.5, 155.3, 150.1, 142.3, 133.7, 130.2, 128.9, 122.9, 114.9, 66.3, 55.5, 55.2, 54.0, 32.6, 26.9. LC–MS: purity 100.00%, $t_R = 4.17$, (ESI) m/z $[M + H]^+$ 387.22. HRMS (MALDI): m/z $[M + H]^+$ 387.2434.

4.1.2.16. 2-(4-(4-(tert-Butylphenoxy)butyl)piperazin-1-yl)pyrazine Oxalate (16). Compound previously described in the literature.¹⁹ White solid, yield 61%. RP-HPLC: 100.00% ($t_R = 2.874$, $k' = 14.13$). LC–MS: purity 98.64%, $t_R = 5.38$, (ESI) m/z $[M + H]^+$ 370.51.

4.2. pH-Dependent Crystallization and Crystal Structure Determination.

Single crystals were obtained by crystallization in two sets of samples, oxalate salts of compounds KSK67 and KSK68, followed by free base samples of KSK67_{fb}, KSK68_{fb}, KSK94_{fb}, and 12_{fb}. The KSK67 and KSK68 oxalate salts were initially crystallized by slow evaporation of the solvent at ambient conditions from propan-2-ol solution with few drops of water. This procedure resulted in obtaining crystals suitable for the X-ray experiment. In the next step, the attempts to crystallize the mentioned samples in three batches were conducted: (1) from the water solution (solution pH: 4.5–5) and (2) with the addition of 1 M HCl (the solution pH: 3.5) and (3) 1 M NaOH (solution pH: 7–7.5). KSK68 is more soluble in H₂O than KSK67. The solubility of both samples increases in acidic conditions, whereas the addition of alkali leads to rapid precipitation. The controlled, dropwise addition of NaOH allowed obtaining a clear solution at equilibrium. The described crystallization procedures of the oxalate salts resulted in good quality crystals only for KSK68 with addition of NaOH (named as KSK68_{OH}). The free base samples of KSK67_{fb}, KSK68_{fb}, KSK94_{fb}, and 12_{fb} are not highly soluble

in water. To solve all samples, an addition of organic solvents mixture was required: propan-2-ol and acetone (2:1, v:v; for **KSK67_fb** and **KSK68_fb**) or propan-2-ol, acetone, and THF (2.5:1, v:v:v; for **KSK94_fb** and **12_fb**). The final pH of solutions was in the range 6.5–7. All samples showed very good solubility in acidic conditions (pH 3.5) and were insoluble after adding the NaOH solution. The above described crystallization procedures of free bases resulted in good quality crystals only for the water/organic solutions. X-ray single-crystal diffraction data sets were collected using an XtaLAB Synergy-S four-circle diffractometer with a mirror monochromator and a microfocus Cu K α radiation source ($\lambda = 1.5418 \text{ \AA}$). The CryoStream cryostat system was used to allow low-temperature experiments performed at 100(2) K. The obtained data sets were processed with the CrysAlisPro software (Rigaku-Oxford Diffraction; CrysAlisPro Oxford Diffraction Ltd., Abingdon, England, V 1. 171. 36. 2 (release 27-06-2012 CN) 2006). The phase problem was solved with direct methods using SHELXT.⁵⁶ Parameters of the obtained model were refined by full-matrix least-squares on F^2 using SHELXL-2014/6.⁵⁷ Calculations were performed using the WinGX integrated system (ver. 2014.1).⁵⁸ Figures were prepared with the Mercury 4.0 software.⁵⁹ All nonhydrogen atoms were refined anisotropically. All hydrogen atoms attached to carbon atoms were positioned with the idealized geometry and refined using the riding model with the isotropic displacement parameter $U_{\text{iso}}[\text{H}] = 1.2 U_{\text{eq}}[\text{C}]$. The hydrogen atoms attached to nitrogens (N1 and/or N10) as a result of protonation of the basic center were located on the Fourier difference map. Hydrogen atoms of water molecules present in the crystal lattice were, in most cases, defined based on the Fourier difference map and were refined using the riding model with the isotropic displacement parameter $U_{\text{iso}}[\text{H}] = 1.5 U_{\text{eq}}[\text{O}]$. In many cases, restraints on distances and angles (DFIX and DANG commands, respectively) were required to maintain relatively good water molecule geometry. Only for structure **KSK67**, where interpretation of the Fourier difference map did not allow water molecules' hydrogen atoms location, was the CALC-OH predictive algorithm⁶⁰ available in the WinGX suite⁵⁸ applied. In structures **KSK67**, **KSK68_fb**, and **KSK94_fb**, a positional disorder within the molecule was observed. This disorder was modeled based on the Fourier difference map inspection, and the site occupancies were determined during the refinement procedure. Crystal data and refinement results are shown in Tables S1 (for oxalate salts) and S2 (for free bases) in the Supporting Information file. The asymmetric units of all obtained crystal structures, presenting atom labeling as well as the positional disorder observed for tested compounds, are shown in Figures S1–S7 in the SI file. Crystallographic data have been deposited with the Cambridge Crystallographic Data Centre (CCDC) as supplementary publication nos. CCDC2245077 (**KSK67**), CCDC2245079 (**KSK68**), CCDC2245081 (**KSK68_OH**), CCDC2245080 (**KSK67_fb**), CCDC2245078 (**KSK68_fb**), CCDC2245082 (**KSK94_fb**), and CCDC2245083 (**12_fb**). Copies of the data can be obtained, free of charge, on application to CCDC (e-mail: deposit@ccdc.cam.ac.uk).

4.3. Potentiometric Titration. The potentiometric microtitration was performed in a thermostated 20 mL cell using a CerkoLab microtitration unit fitted with a pH electrode (Hydromet ERH-13-6). The electrode was calibrated with the use of buffer solutions: pH = 4.00, 7.00, and 10.00. Titrant T (0.1 M KOH) was standardized according to the general analytical procedure and protected from carbon dioxide. Double distilled water with a conductivity of about 0.18 mS/cm was used to prepare all aqueous solutions. DMSO (HPLC grade, 99.5%) was supplied by Sigma Aldrich. The concentration of the titrant solution (D) was 0.0025–0.005 M. The solubilization procedure was as follows: The appropriate amount of KSK compound was dissolved in 1 mL 0.1 M HCl and 1 mL DMSO to prepare a 25 mL stock solution. The developed solubilization system can be recommended for poorly soluble derivatives. The analytical procedure was as follows: volume $V_0 = 4.5 \text{ mL}$ of titrant D was titrated with 0.1 M titrant T using the CerkoLab System equipped with a 5 mL syringe pump. Titrant T was added to titrant D in 0.005 mL increments with 10 s intervals. pK_a values were calculated from the

experimental data points $\{(V_j, \text{pH}_j)/j = 1, \dots, N\}$ according to the Kostrowicki and Liwo algorithm.^{29,30}

4.4. NMR Spectroscopy Measurements in the pH-Controlled Environment. NMR spectra were measured on a JEOL JNM-ECZR 600 MHz spectrometer equipped with a Royal HFX probe. All measurements were carried out at stable 303 K. DMSO- d_6 of purity 99.8% was purchased from Eurisotop and stored over A3 molecular sieves for a few days. Proton spectra were collected from 16 scans and 32,768 points with an acquisition time of 2.42 s and relaxation delay of 5 s. A standard sequence with one 45° pulse on the proton channel before acquisition was used. Titrations were conducted using trifluoromethylsulfonic (triflic) acid purchased from Sigma-Aldrich with a purity of over 99%. A solution of 0.5 M concentration in DMSO- d_6 was made and further used. Analysis of the results was carried out using the JEOL JASON software. Titrations were performed by adding successive portions of the TfOH acid solution to the test compound solution in portions of 0.2 molar equivalents. All spectra and chemical shift tables from the titration experiments are available in the Supporting Information.

4.5. In Vitro Pharmacology.
4.5.1. Affinity at σ_1 and σ_2 Receptors. Brain and liver homogenates for σ_1 R and σ_2 R binding assays were prepared from male Dunkin-Hartley guinea pigs and Sprague-Dawley rats, respectively (ENVIGO RMS S.R.L., Udine, Italy), as previously reported.^{23,61,62} *In vitro* σ_1 R ligand binding assays were carried out in a Tris buffer (50 mM, pH 7.4) for 150 min at 37 °C. The thawed membrane preparation of the guinea pig brain cortex was incubated with increasing concentrations of test compounds and [^3H](+)-pentazocine (2 nM) in a final volume of 0.5 mL. Unlabeled (+)-pentazocine (10 μM) was used to measure nonspecific binding. Bound and free radioligands were separated by fast filtration under reduced pressure using a Millipore filter apparatus through Whatman GF 6 glass fiber filters, which were presoaked in a 0.5% poly(ethyleneimine) water solution. Each filter paper was rinsed three times with ice-cold Tris buffer (50 mM, pH 7.4), dried at rt, and incubated overnight with scintillation fluid into pony vials. The bound radioactivity was determined using a liquid scintillation counter (Beckman LS 6500).^{61,63} *In vitro* σ_2 R ligand binding assays were carried out in Tris buffer (50 mM, pH 8.0) for 120 min at rt. The thawed membrane preparation of rat liver was incubated with increasing concentrations of test compounds and [^3H]DTG (2 nM) in the presence of (+)-pentazocine (5 μM) as σ_1 masking agent in a final volume of 0.5 mL. Nonspecific binding was evaluated with unlabeled DTG (10 μM). Bound and free radioligands were separated by fast filtration under reduced pressure using a Millipore filter apparatus through Whatman GF 6 glass fiber filters, which were presoaked in a 0.5% poly(ethyleneimine) water solution. Each filter paper was rinsed three times with ice-cold Tris buffer (10 mM, pH 8), dried at rt, and incubated overnight with scintillation fluid into pony vials. The bound radioactivity was determined using a liquid scintillation counter (Beckman LS 6500).⁶⁴ The K_i values were calculated with the program GraphPad Prism 7.0 (GraphPad Software, San Diego, CA, USA). The K_i values are given as mean value \pm CI from at least two independent experiments performed in duplicate.

4.5.2. Affinity at Histamine Receptors. Compounds (as oxalate salts) were tested in H_3R *in vitro* binding studies using the methods described previously.^{21–23} Ligands were tested at 5 to 11 appropriate concentrations in a [^3H]N $^{\alpha}$ -methylhistamine ($K_D = 3.08 \text{ nM}$) radioligand depletion assay to determine the affinity at human recombinant histamine H_3R stably expressed in HEK-293 cells. Radioligand binding experiments at the H_1R , H_2R , and H_4R were performed as previously described in Rosier et al.⁶⁵ and Bartole et al.⁶⁶ The following radioligands and concentrations were used: [^3H]mepyramine (h H_1R , $K_D = 5.1 \text{ nM}$, $c = 5 \text{ nM}$) (Novandi Chemistry AB, Södertälje, Sweden), [^3H]UR-DE257 (h H_2R , $K_D = 66.9 \text{ nM}$, $c = 50 \text{ nM}$),⁶⁷ and [^3H]UR-PI294 (h H_4R , $K_D = 3.6 \text{ nM}$, $c = 4 \text{ nM}$)⁶⁸ at HEK293T-SP-FLAG-h H_xR ($x = 1, 2, \text{ or } 4$) expressing the respective hHR. Data represent mean values \pm CI from three independent experiments, each performed in triplicate. The normalized competition binding curves were then fitted with a four-

parameter logistic fit yielding IC_{50} values using the Prism 8.4.3 software (GraphPad, San Diego, CA). The K_i values were estimated from the Cheng–Prusoff equation.⁶⁹

4.5.3. Cyclic Adenosine Monophosphate (cAMP) Accumulation Assay. The LANCE Ultra cAMP assay (Perkin Elmer), a homogeneous time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, is designed to measure cAMP produced upon modulation of adenylyl cyclase activity by GPCRs. The assay is based on the competition between the europium (Eu) chelate-labeled cAMP tracer and sample cAMP for binding sites on cAMP-specific monoclonal antibodies labeled with the ULight dye. For measurement, HEK293 cells expressing hH₃R³⁴ were resuspended in HBSS buffer containing 0.1% BSA, HEPES (5 mM), and phosphodiesterase inhibitor RO-201724 (100 μ M) as previously described.²² An antagonist dose–response experiment was performed in 384-well white opaque plates using 3000 cells/well stimulated with 3 μ M forskolin and 30 nM (R)-(-)- α -methylhistamine as reference H₃R agonist. Cell treatments were performed for 30 min at room temperature, and the cAMP production was assayed by the addition of Eu-cAMP tracer and ULight-anti-cAMP solution in detection buffer according to the manufacturer's instructions. The TR-FRET signal was measured 60 min later using the EnVision microplate reader (Perkin Elmer), and the amount of released cAMP was calculated based on the cAMP standard curve. Experiments were conducted twice in triplicates, and IC_{50} values were determined using the Prism 8.4.3 software.

4.6. In Silico Studies. Molecular Modeling; Docking Studies and Molecular Dynamics Simulations. **4.6.1. Structures of the Receptors.** The histamine H₃ receptor homology model was built using the AlphaFold server,^{70,71} and we chose the model with the highest values of the predicted local-distance difference test (pLDDT). The structures of σ_1 R were retrieved from the Protein Data Bank^{72,73} (PDB ID: 5HK1,⁷⁴ 5HK2,⁷⁴ 6DJZ,⁷⁵ 6DK0,⁷⁵ 6DK1⁷⁵); however, on the basis of the similarity of crystalized ligand and preliminary research, we choose the crystal structure of σ_1 R in complex with the antagonist haloperidol¹⁷ (PDB ID: 6DJZ).

4.6.2. Induced Fit Docking (IFD). The three-dimensional structures of the ligands were prepared using LigPrep v3.6,⁷⁶ and the appropriate ionization states at pH = 7.0 \pm 0.5 were assigned using Epik v3.4.⁷⁷ The Protein Preparation Wizard⁷⁸ was used to assign the bond orders and appropriate amino acid ionization states and to check for steric clashes for the sigma-1 crystals. The receptor grid was generated (OPLS3 force field)⁷⁹ by centering the grid box of the sigma-1 receptor with a size of 8 Å on crystalized ligands and the grid box of histamine H₃R with a size of 10 Å on D3.32. Automated flexible docking was performed using Glide v6.9^{80,81} at the SP level.

4.6.3. The QM/MM Optimization. The L-R complexes selected in IFD procedure were next optimized using the QM/MM approach using QSite.⁸² The QM area containing the ligand and the amino acid side chains interacting with ligands was described by a combination of DFT hybrid functional B3LYP and LACVP* basis sets, whereas the rest of the system was optimized using the OPLS3 force field.

4.6.4. Quantum Polarized Ligand Docking (QPLD). The optimized complexes of KSK68 and 12 were used as a grid for the next steps. The receptor grids were generated (OPLS3 force field) by centering the grid box with a size of 8 Å on KSK68 and 12. Docking was performed by the quantum-polarized ligand docking (QPLD) procedure⁸³ that involves the QM-derived ligand atomic charges in the protein environment at the 3-21G/BLYP level. For each ligand, the five poses were obtained.

4.6.5. Binding Free Energy Calculations. GBSA (generalized-born/surface area) was used to calculate the binding free energy based on the ligand–receptor complexes generated by the QPLD procedure. The ligand poses were minimized using the local optimization feature in Prime, the flexible residue distance was set to 6 Å from a ligand pose, and the ligand charges obtained in the QPLD stage were used. The energies of complexes were calculated with the OPLS3e force field and generalized-born/surface area continuum solvent model. To assess the influence of an appropriate tautomeric and protonation state, the $\Delta\Delta G$ was calculated as a difference between binding free

energy (ΔG) of the piperidine monoprotonated derivative and piperazine analogues.

4.6.6. Molecular Dynamics Simulations. Selected ligand–receptor complexes underwent MD simulations to confirm the stability of docking poses obtained in previous stages. They were carried out in Desmond,¹⁶ with the application of the TIP3P solvent model¹⁷ and POPC membrane model in the case of the H₃R. The remaining conditions were as follows: OPLS3e force-field, pressure of 1.01325 bar, temperature of 300 K, orthorhombic box shape with a size of +10 Å \times +10 Å \times +10 Å, application of the neutralization of the system by addition of the appropriate number of Cl[−] ions and relaxation before simulation, simulation length: 1000 ns. Ligand–protein contacts occurring during MD simulations were analyzed with the use of the Simulation Interaction Diagram (Schrödinger Suite).

4.6.7. Protonation Studies. The protonation studies were carried out in two software packages: InstantJChem and Epik.⁷⁷ In the latter case, water was selected as a solvent.

4.7. Determination of Selected ADMET Parameters. **4.7.1. Permeability across Lipid Membranes.** The precoated PAMPA Plate System Gentest was obtained from Corning (Tewksbury, MA, USA). It consists of a 96-well receiver filter plate that has been precoated with structured layers of phospholipids and a matched donor microplate. The stock solutions of tested compounds and reference drugs were diluted in the PBS buffer (pH 7.4) to the final concentration of 100 μ M according to the method described previously.²¹ The compounds were applied into the donor wells (300 μ L), and PBS buffer was placed in acceptor wells (200 μ L). Plates were incubated in RT for 5 h. By using the UPLC–MS spectrometry (Waters ACQUITY TQD system with the TQ Detector, Waters, Milford, USA) with an internal standard, the exact quantity of molecules that penetrated from donor to acceptor wells through phospholipid membrane was estimated. The permeability coefficients (P_e , cm/s) were calculated using the formula provided by the PAMPA Plate System manufacturer.⁴⁹

4.7.2. Serum Metabolic Stability. Acetonitrile (LC–MS grade), formic acid (LC–MS grade), and DMSO (HPLC grade) were obtained from Sigma Aldrich. Imipramine was also acquired from Sigma Aldrich. Water MilliQ was used for chromatography with 18 M Ω -cm.

The plasma was warmed to 37 °C for 10 min, mixed, and centrifuged to pellet any aggregated protein. Calcium chloride (500 mM, 0.5 mL added to 25 mL of plasma) was then added to the plasma to allow clot formation. The plasma was centrifuged at 4 °C for 30 min at 14,000 rpm to remove the clot. The clear supernatant (serum) was then transferred to an assay plate (249 μ L) using the Bravo Automated Liquid Handling Platform (Agilent Technologies). The serum was equilibrated to 37 °C, and biotransformation was initiated by adding 1 μ L of the compound solution in DMSO to achieve final concentrations of 0.1, 0.5, and 1 mM with 250 μ L final incubation volume. Samples (25 μ L) were taken at 0, 1, 2, 4, 6, and 24 h and added to 100 μ L acetonitrile with 100 nM imipramine as internal standard for plasma deproteinization. The samples were vortexed for 1 min and then centrifuged at 4 °C for 30 min at 14,000 rpm. The clear supernatants were analyzed by LC–MS. An Exion HPLC system consisting of a degasser (DGPU-20A) and an autosampler (SIL-HTA) was used. LC was performed on an analytical column (Waters BEH C18; 1.7 μ m, 50 \times 2.1 mm). The mobile phase consisted of acetonitrile–water with 0.1% formic acid. The flow rate was 0.5 mL/min with a column compartment temperature of 50 °C and injection volume of 1 μ L.

4.8. In Vivo Pharmacology. **4.8.1. Influence on Spontaneous Locomotor Activity.** This test was carried out according to the procedure described elsewhere.⁸⁴ The animals were injected (i.p.) with 12 at doses of 5, 15, and 30 mg/kg and placed in the activity cages individually (30 min before the experiment). The number of light-beam crossings was counted in each group during the next 30 min in 10 min intervals.

4.8.2. Influence on Motor Coordination in the Rotarod Test. The test was carried out on the semiautomatic rotarod apparatus (Rotarod apparatus Panlab/Harvard Apparatus, LE 8200, Spain) according to

the method previously described in the literature.⁸⁵ The mice were trained for 3 days on the rod rotating at a constant speed of 18 rotations per minute (rpm). During each training session, the animals were placed on the rod for 3 min with an unlimited number of trials. On the test day (24 h after the final training trial), 30 min before the rotarod test, the mice were pretreated (i.p.) with the test compound (15 mg/kg). Then, the animals were tested on the rotarod revolving at 6, 18, and then 24 rpm. Motor impairments, defined as the inability to remain on the rotating rod for 1 min, were measured at each speed.

4.8.3. Formalin Test. The procedure used was essentially the same as that described previously.^{86,87} Briefly, 20 μ L of 1.5% formalin solution was injected intraplantarly (i.pl.) into the mice right hind paw using a 26-gauge needle. Immediately after formalin injection, the animals were placed individually in an observation chamber made of glass and were observed for the next 30 min. The total time (in seconds) spent on licking the injected paw during periods of 0–5 min (early phase, neurogenic) and 15–30 min (late phase, inflammatory) was measured and was considered as an indicator of nociceptive behavior. Before formalin injection, different groups of mice were treated i.p. with the vehicle (10 mL/kg, negative control) and the varying doses of **12** (5, 10, 15, and 30 mg/kg).

4.8.4. Capsaicin-Induced Nociception. The procedure used was similar to that described previously.^{88,89} The pain reaction was induced by the injection of 20 μ L of capsaicin solution (1.6 μ g/paw made in PBS) under the skin of the dorsal surface of the mice right hindpaw. The animals were observed individually in an observation chamber for 5 min following capsaicin injection. The amount of time spent licking the injected paw was recorded by means of the stopwatch and was considered as indicative of pain. The animals were pretreated with the vehicle (10 mL/kg, negative control) and investigated compound (**10**, **15**, and **30** mg/kg).

4.8.5. Loperamide-Induced Antinociception. Female CD1 mice (Charles River, Barcelona, Spain) were used in all experiments. The experiments were performed during the light phase (from 9:00 a.m. to 3:00 p.m.). Animal care was provided in accordance with institutional (Research Ethics Committee of the University of Granada, Granada, Spain), regional (Junta de Andalucía, Spain), and international standards (European Communities Council directive 2010/63).

We aimed to test whether compound **12** behaved *in vivo* as σ_1 antagonists or agonists. As reference σ_1 compounds, we used **SIRA** (4-[2-[[5-methyl-1-(2-naphthalenyl)1H-pyrazol-3-yl]oxy]ethyl]-morpholine hydrochloride), a known selective σ_1 receptor antagonist (DC Chemicals, Shanghai, China), and **PRE-084** (2-[4-morpholinethyl]1-phenylcyclohexanecarboxylate hydrochloride) (Tocris Cookson Ltd., Bristol, United Kingdom), a selective σ_1 receptor agonist.¹⁸ **SIRA** and **PRE-084** were dissolved in sterile physiologic saline (0.9% NaCl). Compound **12** was dissolved in 2% Tween 80 (Sigma-Aldrich, Madrid, Spain) in ultrapure water and heated until dissolved before injection. We previously tested that this solvent did not alter the animals' behavioral response to the mechanical stimulation (data not shown). All these compounds (or their solvents) were administered intraplantarly (i.pl.) into the right hind paw in a volume of 20 μ L using a 1710 TLL Hamilton microsyringe (Teknokroma, Barcelona, Spain) with a 30^{1/2}-gauge needle. The i.pl. injection was made 5 min before nociceptive testing to minimize systemic absorption of the compounds. When **PRE-084** was associated with **SIRA** or **12**, drugs were dissolved in the same solution and injected together to avoid paw lesions from multiple injections.

As it is known that σ_1 antagonism can enhance opioid antinociception and that σ_1 agonism reverses this effect,⁹⁰ we tested whether our compound modulated the antinociceptive effect induced by the opioid agonist loperamide hydrochloride (Sigma-Aldrich). This drug was dissolved in 1% dimethylsulfoxide (DMSO) (Merck KGaA, Darmstadt, Germany) in ultrapure water and injected subcutaneously into the interscapular area in a volume of 5 mL/kg 30 min before behavioral testing. Naloxone methiodide (Sigma-Aldrich) was used as a peripheral opioid antagonist⁹¹ and was dissolved in physiological saline and s.c. administered 5 min before loperamide injection.

Nociceptive stimulation of the hind paw of the animals was made with an Analgesimeter (Model 37215, Ugo-Basile, Varese, Italy) as previously described.^{23,90} After drug administration, mice were gently pincer grasped between the thumb and index fingers by the skin above the interscapular area. Then, a blunt cone-shaped paw-presser was applied at a constant intensity of 450 g to the dorsal surface of the hind paw until the animal showed a struggle response. The struggle latency was measured with a chronometer. Evaluations were done twice alternately to each hind paw at intervals of 1 min between stimulations.

Statistical analysis was carried out with the two-way analysis of variance (ANOVA) followed by a Bonferroni *post hoc* test. ANOVA was performed with the SigmaPlot 12.0 program. The differences between values were considered significant when the *p* value was below 0.05.

4.8.6. Oxaliplatin-Induced Neuropathy. Neuropathy was induced by the administration of a single dose (10 mg/kg) of oxaliplatin (OXPT) dissolved in a 5% glucose solution (Polfa Kutno, Poland). To assess the sensitivity to mechanical stimuli, the von Frey test was carried out using the electronic von Frey unit (Bioseb, France). The apparatus was supplied with a single flexible filament, which was used to apply increasing force (from 0 to 10 g) against the plantar surface of the hind paw of the mouse. The crossing of pain threshold resulted in the paw withdrawal and subsequent recording of the mechanical pressure that evoked the nocifensive response. The measurement was done before the OXPT administration and 3 h and 7 days afterward. The compounds were administered to the animals with tactile allodynia observed as a statistically significant decrease in pain threshold. On the day of the experiment, each mouse was placed in an observation chamber with a wire mesh bottom and was allowed to habituate for 1 h. After the habituation period, the mouse pain threshold was tested three times alternately with at least 30 s gap between each measurement. The mean of these three consecutive measurements was taken as the baseline value. The mice with tactile allodynia were i.p. pretreated with the tested compound, and 30 min later, the animals were tested again according to the same procedure.⁹²

4.8.7. Chronic Constriction Injury of the Sciatic Nerve. All animal procedures were performed following the recommendations of the International Association for the Study of Pain⁹³ and the NIH Guide for the Care and Use of Laboratory Animals. Experiments were approved by the II Local Ethics Committee Branch of the National Ethics Committee for Experiments on Animals based at the Maj Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland (approval number: 24/2022). Care was taken to minimize animal suffering and minimize the number of animals used (3R policy). Adult male albino Swiss CD-1 mice (initially weighing 18–20 g) were purchased from Charles River Laboratories (Hamburg, Germany). The animals were housed in groups of seven under controlled conditions (temp. 21 \pm 2 °C; 12 h light/dark cycle, lights on at 6:00 a.m.) with *ad libitum* food and water.

The model of chronic constriction injury (CCI) to the sciatic nerve was established according to Bennett and Xie.⁹⁴ The surgical method was performed under isoflurane anesthesia (2% isoflurane in 100% oxygen with a flow of 1.5 L/min).⁹⁵ Below the right hipbone, a small incision was performed, and three ligatures (4/0 silk) around the sciatic nerve were made (with 1 mm spacing) until a brief twitch in the respective hind limb was observed. All mice that underwent the CCI procedure developed hypersensitivity to mechanical and thermal stimuli. Behavioral tests were performed at day 14 after injury. Compound **12** was dissolved in 10% DMSO/10% (2-hydroxypropyl)- β -cyclodextrin/water and administered i.p. at doses 5, 10, and 15 mg/kg (injection volume 10 mL/kg of body weight). The control group received the vehicle (10% DMSO/10% (2-hydroxypropyl)- β -cyclodextrin/water).

4.8.7.1. Behavioral Tests. Behavioral experiments were performed between 8:00 a.m. and 2:00 p.m. Across the experiments, we compared vehicle-treated mice with **12**-treated animals. Experiments were performed 30, 90, and 180 min (von Frey test); 35, 95, and 185

min (cold plate test); and 40, 100, and 190 min (tail flick test) after the vehicle or 12 administration.

The von Frey test was used to measure mechanical hypersensitivity as described in a previous publication.⁹⁵ The animals were placed in cages with a wire net floor. The reaction (paw withdrawal, shaking, or licking) of the ipsilateral (Figure 15) and contralateral (Figure S33) paw of CCI-exposed mice to the mechanical stimulator (calibrated nylon monofilaments (0.6–6 g; Stoelting)) in serial increments was observed.

Sensitivity to noxious thermal stimuli was assessed with the cold plate test (Cold/Hot Plate Analgesia Meter, Columbus Instruments) as previously described.⁹⁵ The temperature of the plate was kept at 2 °C, and the cutoff latency was 30 s. The mice were placed on the cold plate, and the time until lifting of the injured paw was recorded.

The responsiveness to thermally induced pain was determined by a tail flick analgesic meter (Tail-Flick Unit; Ugo Basile) as previously described.⁹⁵ Tail flick latency was measured on the dorsal part of the tail at two-thirds of its length by applying a focused beam of light (thermal stimulus). The time interval between onset of the thermal stimulus and withdrawal of the tail from the beam was recorded; the cutoff latency was 9 s to prevent tissue damage.

4.8.7.2. Data and Statistical Analysis. The behavioral data in Figure 14 are presented as a percentage of the maximal possible effect [% MPE = 100% × (measured response – basal)/(cutoff value – basal)] of drug action. In the Supporting Information, the results from the von Frey test are expressed as pressure (g) applied with the filament. The behavioral data are presented as mean ± SEM. The one-way ANOVA was performed, and the differences between the groups were further analyzed with Bonferroni's *post hoc* test. Significant differences between group are indicated when **p* < 0.05, ***p* < 0.01, and ****p* < 0.001. The analysis and charts were prepared using GraphPad Prism v.9.1.2 (GraphPad Software, La Jolla, CA, USA).

■ ASSOCIATED CONTENT

SI Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c00430>.

Protonation investigation based on crystal structure analysis; determination of the basicity of selected piperidine and piperazine derivatives by potentiometric titration; protonation investigation based on NMR spectroscopy measurements in pH-controlled environment; *in vivo* pharmacological activity; *in silico* studies; molecular modeling: docking studies and molecular dynamics simulations; and ¹H and ¹³C NMR spectra HRMS analysis and HPLC traces (PDF)

Molecular formula strings (CSV)

3_in_H3 (PDB)

3_in_sigma1 (PDB)

7_in_H3 (PDB)

7_in_sigma1 (PDB)

H3_compound_3 (PDB)

H3_compound_7 (PDB)

KSK67_in_H3_pose1 (PDB)

KSK67_in_H3_pose2 (PDB)

KSK68_in_H3 (PDB)

KSK94_in_sigma1_pose1 (PDB)

KSK94_in_sigma1_pose2 (PDB)

KSK100_in_sigma1 (PDB)

sigma_compound_3 (PDB)

sigma_compound_7 (PDB)

■ AUTHOR INFORMATION

Corresponding Authors

Tadeusz Karcz – Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland; Email: t.karcz@uj.edu.pl

Emanuele Amata – Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy; orcid.org/0000-0002-4750-3479; Email: eamata@unict.it

Katarzyna Kieć-Kononowicz – Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland; Email: mfkonono@cyf-kr.edu.pl

Authors

Katarzyna Szczepańska – Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland; Department of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Kraków, Poland; orcid.org/0000-0002-6110-9400

Maria Dichiara – Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy; orcid.org/0000-0001-6380-7176

Szczepan Mogilski – Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland

Justyna Kalinowska-Tłuścik – Department of Crystal Chemistry and Crystal Physics, Faculty of Chemistry, Jagiellonian University, 30-387 Kraków, Poland

Bogusław Pilarski – Cerko Sp. z o.o. Sp.k, 81-451 Gdynia, Poland

Arkadiusz Leniak – Celon Pharma S.A., R&D Centre, 05-152 Kazuń Nowy, Poland

Wojciech Pietruś – Department of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Kraków, Poland; Celon Pharma S.A., R&D Centre, 05-152 Kazuń Nowy, Poland; orcid.org/0000-0002-8563-7929

Sabina Podlewska – Department of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Kraków, Poland; orcid.org/0000-0002-2891-5603

Katarzyna Popiołek-Barczyk – Department of Neurochemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Kraków, Poland

Laura J. Humphrys – Institute of Pharmacy, Faculty of Chemistry and Pharmacy, University of Regensburg, D-93053 Regensburg, Germany; orcid.org/0000-0003-4019-5538

M. Carmen Ruiz-Cantero – Department of Pharmacology and Neurosciences Institute (Biomedical Research Center), University of Granada, and Biosanitary Research Institute ibs. Granada, 18016 Granada, Spain; orcid.org/0000-0001-6968-0946

David Reiner-Link – Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany

Luisa Leitzbach – Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany

Dorota Łażewska – Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland; orcid.org/0000-0001-8454-4440

Steffen Pockes – Institute of Pharmacy, Faculty of Chemistry and Pharmacy, University of Regensburg, D-93053 Regensburg, Germany; orcid.org/0000-0002-2211-9868

Michał Górka – Celon Pharma S.A., R&D Centre, 05-152 Kazuń Nowy, Poland

Adam Zmysłowski – Celon Pharma S.A., R&D Centre, 05-152 Kazuń Nowy, Poland

Thierry Calmels – Bioprojet-Biotech, 4rue du Chesnay Beaugregard, 35762 Saint-Gregoire, France

Enrique J. Cobos – Department of Pharmacology and Neurosciences Institute (Biomedical Research Center), University of Granada, and Biosanitary Research Institute ibs. Granada, 18016 Granada, Spain

Agostino Marrazzo – Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy; orcid.org/0000-0002-8728-8857

Holger Stark – Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany; orcid.org/0000-0003-3336-1710

Andrzej J. Bojarski – Department of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Kraków, Poland; orcid.org/0000-0003-1417-6333

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acs.jmedchem.3c00430>

Author Contributions

◇K.S. and T.K. contributed equally. K.K.-K., K.S., T.K., H.S., E.A., S.Poc., A.M., and A.J.B. participated in research design. K.S. and D.Ł. synthesized, purified, and characterized all compounds. J.K.-T. conducted crystallographic experiments. B.P. conducted potentiometric titrations. A.L. conducted NMR analysis in a pH-controlled environment. M.D., L.H., D.R.-L., L.L., T.C., M.G., A.Z., and T.K. conducted *in vitro* experiments. S.M., K.P.-B., M.C.R.C., and E.J.C. conducted *in vivo* pharmacology experiments. S.Pod. and W.P. conducted *in silico* experiments. K.S., M.D., and M.C.R.C. contributed reagents, materials, and analysis tools. K.S. and T.K. performed data analysis. K.S. wrote the original draft. T.K. and J.K.-T. wrote and contributed to the writing of the manuscript. All authors have given approval to the final version of the manuscript.

Funding

We are pleased to acknowledge the generous support of the National Science Center, Poland, granted based on decisions 2020/36/C/NZ7/00284, 2019/35/D/NZ7/01042, and 2020/04/X/NZ7/01338. This study was partly supported by statutory funds from the Faculty of Pharmacy Jagiellonian University Medical College, Krakow, Poland (N42/DBS/000242). Support by ERNEST COST Action 18133 is also acknowledged. We also acknowledge funding from the University of Catania, PIA.CE.RI. 2020–2022 Linea di intervento 3 Starting Grant project CARETO (grant 57722172136 to E. Amata). S.Poc. was supported by the Fonds der Chemischen Industrie (grant 661688). L.J.H. was funded by the Deutsche Forschungsgemeinschaft (DFG, Research Training Group GRK 1910). The crystal structure analysis was performed on the equipment purchased thanks to the financial support of the Ministry of Science and Higher Education, Warsaw, Poland (grant 6903/IA/SP/2018).

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We would like to thank Maria Kaleta and Annika Frank for technical assistance.

ABBREVIATIONS

ADME, absorption, distribution, metabolism, excretion; br, broad; cAMP, 3',5'-cyclic adenosine monophosphate; CC, column chromatography; CCDC, Cambridge Crystallographic Data Centre; CCI, chronic constriction injury; CI, confidence interval; CNS, central nervous system; d, doublet; dd, doublet of doublets; DMSO, dimethyl sulfoxide; GPCR, G protein-coupled receptor; H₁R, histamine H₁ receptor; H₂R, histamine H₂ receptor; H₃R, histamine H₃ receptor; HB, hydrogen bond; HEK, human embryonic kidney cells; HPLC, high-performance liquid chromatography; HRMS, high-resolution mass spectra; i.p., intraperitoneal; IFD, induced fit docking; m.p., melting point; m, multiplet; MD, molecular dynamics; MM-GBSA, molecular mechanics generalized born surface area; MPE, maximum possible effect; MTDLs, multitarget-directed ligands; NMDA, N-methyl-D-aspartate receptor; NMR, nuclear magnetic resonance spectroscopy; OXPt, oxaliplatin; PAMPA, parallel artificial membrane permeability assay; PDB, Protein Data Bank; P_e, permeability coefficient; ppm, parts per million; qd, quartet of doublets; QPLD, quantum polarized ligand docking; quin, quintet; RMSD, root-mean-square deviation; RT, room temperature; s.c., subcutaneous; s, singlet; SD, standard deviation; SEM, standard error of the mean; t, triplet; TfOH, trifluoromethanesulfonic acid (triflic acid); TLC, thin-layer chromatography; t_R, retention time; TR-FRET, time-resolved fluorescence resonance energy transfer; TRPV1, transient receptor potential vanilloid type 1; tt, triplet of triplets; UPLC-MS, ultra-performance liquid chromatography-mass spectrometry; σ₁R, sigma-1 receptor; σ₂R, sigma-2 receptor

REFERENCES

- (1) Zimmermann, G. R.; Lehár, J.; Keith, C. T. Multi-target therapeutics: when the whole is greater than the sum of the parts. *Drug Discovery Today* **2007**, *12*, 34–42.
- (2) Proschak, E.; Stark, H.; Merk, D. Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds. *J. Med. Chem.* **2019**, *62*, 420–444.
- (3) Walter, M.; Stark, H. Histamine receptor subtypes: a century of rational drug design. *Front Biosci* **2012**, *S4*, 461–488.
- (4) Łazewska, D.; Kiec-Kononowicz, K. New developments around histamine H(3) receptor antagonists/inverse agonists: a patent review (2010 - present). *Expert Opin. Ther. Pat.* **2014**, *24*, 89–111.
- (5) Hsieh, G. C.; Honore, P.; Pai, M.; Wensink, E. J.; Chandran, P.; Salyers, A. K.; Wetter, J. M.; Zhao, C.; Liu, H.; Decker, M. W.; Esbenshade, T. A.; Cowart, M. D.; Brioni, J. D. Antinociceptive effects of histamine H₃ receptor antagonist in the preclinical models of pain in rats and the involvement of central noradrenergic systems. *Brain Res.* **2010**, *1354*, 74–84.
- (6) Ghamari, N.; Zarei, O.; Arias-Montaño, J. A.; Reiner, D.; Dastmalchi, S.; Stark, H.; Hamzeh-Mivehroud, M. Histamine H₃ receptor antagonists/inverse agonists: Where do they go? *Pharmacol. Ther.* **2019**, *200*, 69–84.
- (7) European Medicines Agency *Wakix (pitolisant) - Assessment report*; 2015;44 (November), 1–91.
- (8) Imeri, F.; Stepanovska Tanturovska, B.; Zivkovic, A.; Enzmann, G.; Schwalm, S.; Pfeilschifter, J.; Homann, T.; Kleuser, B.; Engelhardt, B.; Stark, H.; Huwiler, A. Novel compounds with dual S1P receptor agonist and histamine H₃ receptor antagonist activities act protective in a mouse model of multiple sclerosis. *Neuropharmacology* **2021**, *186*, No. 108464.

- (9) Szczepańska, K.; Kincses, A.; Vincze, K.; Szymańska, E.; Latacz, G.; Kuder, K. J.; Stark, H.; Spengler, G.; Handzlik, J.; Kieć-Kononowicz, K. N-Substituted piperazine derivatives as potential multitarget agents acting on histamine H₃ receptor and cancer resistance proteins. *Bioorg. Med. Chem. Lett.* **2020**, *30*, No. 127522.
- (10) Reiner, D.; Seifert, L.; Deck, C.; Schüle, R.; Jung, M.; Stark, H. Epigenetics meets GPCR: inhibition of histone H3 methyltransferase (G9a) and histamine H₃ receptor for Prader-Willi Syndrome. *Sci. Rep.* **2020**, *10*, 13558.
- (11) Bautista-Aguilera, Ó. M.; Hagenow, S.; Palomino-Antolin, A.; Farré-Alins, V.; Ismaili, L.; Joffrin, P.-L.; Jimeno, M. L.; Soukup, O.; Janočková, J.; Kalinowsky, L.; Proschak, E.; Iriepa, I.; Moraleda, I.; Schwed, J. S.; Romero Martínez, A.; López-Muñoz, F.; Chioua, M.; Egea, J.; Ramsay, R. R.; Marco-Contelles, J.; Stark, H. Multitarget-Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H₃ R Antagonism for Neurodegenerative Diseases. *Angew. Chem., Int. Ed. Engl.* **2017**, *56*, 12765–12769.
- (12) Łażewska, D.; Bajda, M.; Kaleta, M.; Zareba, P.; Doroz-Płonka, A.; Siwek, A.; Alachkar, A.; Mogilski, S.; Saad, A.; Kuder, K.; Olejarz-Maciej, A.; Godyń, J.; Stry, D.; Sudoł, S.; Więcek, M.; Latacz, G.; Walczak, M.; Handzlik, J.; Sadek, B.; Malawska, B.; Kieć-Kononowicz, K. Rational design of new multitarget histamine H₃ receptor ligands as potential candidates for treatment of Alzheimer's disease. *Eur. J. Med. Chem.* **2020**, *207*, No. 112743.
- (13) Riddey, D. M.; Cook, A. E.; Shackelford, D. M.; Pierce, T. L.; Mocaer, E.; la Cour, C. M.; Sors, A.; Charman, W. N.; Summers, R. J.; Sexton, P. M.; Christopoulos, A.; Langmead, C. J. Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H₃ receptor antagonists. *Neuropharmacology* **2019**, *144*, 244–255.
- (14) Leurs, R.; Tulp, M. T. M.; Menge, W. M. B. P.; Adolfs, M. J. P.; Zuiderveld, O. P.; Timmerman, H. Evaluation of the receptor selectivity of the H₃ receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5-HT₃ receptor revealed. *Br. J. Pharmacol.* **1995**, *116*, 2315–2321.
- (15) Turnaturi, R.; Montenegro, L.; Marrazzo, A.; Parenti, R.; Pasquinucci, L.; Parenti, C. Benzomorphan skeleton, a versatile scaffold for different targets: A comprehensive review. *Eur. J. Med. Chem.* **2018**, *155*, 492–502.
- (16) Arena, E.; Dichiara, M.; Floresta, G.; Parenti, C.; Marrazzo, A.; Pittalà, V.; Amata, E.; Prezzavento, O. Novel Sigma-1 receptor antagonists: from opioids to small molecules: what is new? *Future Med. Chem.* **2018**, *10*, 231–256.
- (17) Cobos, E. J.; Entrena, J. M.; Nieto, F. R.; Cendán, C. M.; Del Pozo, E. Pharmacology and therapeutic potential of sigma(1) receptor ligands. *Curr. Neuropharmacol.* **2008**, *6*, 344–366.
- (18) Ruiz-Cantero, M. C.; González-Cano, R.; Tejada, M. Á.; Santos-Caballero, M.; Perazzoli, G.; Nieto, F. R.; Cobos, E. J. Sigma-1 receptor: A drug target for the modulation of neuroimmune and neuroglial interactions during chronic pain. *Pharmacol. Res.* **2021**, *163*, No. 105339.
- (19) Szczepańska, K.; Karcz, T.; Mogilski, S.; Siwek, A.; Kuder, K. J.; Latacz, G.; Kubacka, M.; Hagenow, S.; Lubelska, A.; Olejarz, A.; Kotańska, M.; Sadek, B.; Stark, H.; Kieć-Kononowicz, K. Synthesis and biological activity of novel *tert*-butyl and *tert*-pentylphenoxyalkyl piperazine derivatives as histamine H₃R ligands. *Eur. J. Med. Chem.* **2018**, *152*, 223–234.
- (20) Szczepańska, K.; Karcz, T.; Kotańska, M.; Siwek, A.; Kuder, K. J.; Latacz, G.; Mogilski, S.; Hagenow, S.; Lubelska, A.; Sobolewski, M.; Stark, H.; Kieć-Kononowicz, K. Optimization and preclinical evaluation of novel histamine H₃ receptor ligands: Acetyl and propionyl phenoxyalkyl piperazine derivatives. *Bioorg. Med. Chem.* **2018**, *26*, 6056–6066.
- (21) Szczepańska, K.; Karcz, T.; Siwek, A.; Kuder, K. J.; Latacz, G.; Bednarski, M.; Szafarz, M.; Hagenow, S.; Lubelska, A.; Olejarz-Maciej, A.; Sobolewski, M.; Mika, K.; Kotańska, M.; Stark, H.; Kieć-Kononowicz, K. Structural modifications and *in vitro* pharmacological evaluation of 4-pyridyl-piperazine derivatives as an active and selective histamine H₃ receptor ligands. *Bioorg. Chem.* **2019**, *91*, No. 103071.
- (22) Szczepańska, K.; Pockes, S.; Podlewska, S.; Höring, C.; Mika, K.; Latacz, G.; Bednarski, M.; Siwek, A.; Karcz, T.; Nagl, M.; Bresinsky, M.; Mönnich, D.; Seibel, U.; Kuder, K. J.; Kotańska, M.; Stark, H.; Elz, S.; Kieć-Kononowicz, K. Structural modifications in the distal, regulatory region of histamine H₃ receptor antagonists leading to the identification of a potent anti-obesity agent. *Eur. J. Med. Chem.* **2021**, *213*, No. 113041.
- (23) Szczepańska, K.; Podlewska, S.; Dichiara, M.; Gentile, D.; Patamia, V.; Rosier, N.; Mönnich, D.; Ruiz Cantero, M. C.; Karcz, T.; Łażewska, D.; Siwek, A.; Pockes, S.; Cobos, E. J.; Marrazzo, A.; Stark, H.; Rescifina, A.; Bojarski, A. J.; Amata, E.; Kieć-Kononowicz, K. Structural and Molecular Insight into Piperazine and Piperidine Derivatives as Histamine H₃ and Sigma-1 Receptor Antagonists with Promising Antinociceptive Properties. *ACS Chem. Neurosci.* **2022**, *13*, 1–15.
- (24) Łażewska, D.; Kaleta, M.; Schwed, J. S.; Karcz, T.; Mogilski, S.; Latacz, G.; Olejarz, A.; Siwek, A.; Kubacka, M.; Lubelska, A.; Honkisz, E.; Handzlik, J.; Filippek, B.; Stark, H.; Kieć-Kononowicz, K. Biphenyloxy-alkyl-piperidine and azepane derivatives as histamine H₃ receptor ligands. *Bioorg. Med. Chem.* **2017**, *25*, 5341–5354.
- (25) Godyń, J.; Zareba, P.; Łażewska, D.; Stry, D.; Reiner-Link, D.; Frank, A.; Latacz, G.; Mogilski, S.; Kaleta, M.; Doroz-Płonka, A.; Lubelska, A.; Honkisz-Orzechowska, E.; Olejarz-Maciej, A.; Handzlik, J.; Stark, H.; Kieć-Kononowicz, K.; Malawska, B.; Bajda, M. Cyanobiphenyls: Novel H₃ receptor ligands with cholinesterase and MAO B inhibitory activity as multitarget compounds for potential treatment of Alzheimer's disease. *Bioorg. Chem.* **2021**, *114*, No. 105129.
- (26) Rzęsikowska, K.; Jabłoński, M.; Kalinowska-Tłuścik, J. Flat or angular? The impact of the nitrogen atom hybridization on the docking results for arylpiperazine derivatives as an example. *Struct. Chem.* **2020**, *31*, 823–829.
- (27) Pilarski, B.; Kalisz, R.; Wyrzykowski, D.; Młodzianowski, J.; Balińska, A. General analytical procedure for determination of acidity parameters of weak acids and bases. *J. Anal. Methods Chem.* **2015**, *2015*, No. 530731.
- (28) Hogendorf, A. S.; Hogendorf, A.; Popiolek-Barczyk, K.; Ciechanowska, A.; Mika, J.; Satała, G.; Walczak, M.; Latacz, G.; Handzlik, J.; Kieć-Kononowicz, K.; Ponimaskin, E.; Schade, S.; Zeug, A.; Bijata, M.; Kubicki, M.; Kurczab, R.; Lenda, T.; Staroń, J.; Bugno, R.; Duszyńska, B.; Pilarski, B.; Bojarski, A. J. Fluorinated indoleimidazole conjugates: Selective orally bioavailable 5-HT₇ receptor low-basicy agonists, potential neuropathic painkillers. *Eur. J. Med. Chem.* **2019**, *170*, 261–275.
- (29) Kostrowicki, J.; Liwo, A. A general method for the determination of the stoichiometry of unknown species in multi-component systems from physicochemical measurements. *Comput. Chem.* **1987**, *11*, 195–210.
- (30) Kostrowicki, J.; Liwo, A. Determination of equilibrium parameters by minimization of an extended sum of squares. *Talanta* **1990**, *37*, 645–650.
- (31) Khalili, F.; Henni, A.; East, A. L. L. pK_a Values of Some Piperazines at (298, 303, 313, and 323) K. *J. Chem. Eng. Data* **2009**, *54*, 2914–2917.
- (32) Lacivita, E.; Leopoldo, M.; De Giorgio, P.; Berardi, F.; Perrone, R. Determination of 1-aryl-4-propylpiperazine pK_a values: The substituent on aryl modulates basicity. *Bioorg. Med. Chem.* **2009**, *17*, 1339–1344.
- (33) Wilson, L. L.; Alleyne, A. R.; Eans, S. O.; Cirino, T. J.; Stacy, H. M.; Mottinelli, M.; Intagliata, S.; McCurdy, C. R.; McLaughlin, J. P. Characterization of CM-398, a Novel Selective Sigma-2 Receptor Ligand, as a Potential Therapeutic for Neuropathic Pain. *Molecules* **2022**, *27*, 3617.
- (34) Ligneau, X.; Perrin, D.; Landais, L.; Camelin, J. C.; Calmels, T. P.; Berrebi-Bertrand, I.; Lecomte, J. M.; Parmentier, R.; Anacleit, C.; Lin, J. S.; Bertaina-Anglade, V.; la Rochelle, C. D.; d'Aniello, F.; Rouleau, A.; Gbahou, F.; Arrang, J.-M.; Ganellin, C. R.; Stark, H.;

- Schunack, W.; Schwartz, J.-C. BF2.649 [1-{3-[3-(4-Chlorophenyl)-propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H₃ receptor: Preclinical pharmacology. *J. Pharmacol. Exp. Ther.* **2007**, *320*, 365–375.
- (35) Dastmalchi, S.; Hamzeh-Mivehroud, M.; Ghafourian, T.; Hamzei, H. Molecular modeling of histamine H₃ receptor and QSAR studies on arylbenzofuran derived H₃ antagonists. *J. Mol. Graphics Modell.* **2008**, *26*, 834–844.
- (36) Lorenzi, S.; Mor, M.; Bordi, F.; Rivara, S.; Rivara, M.; Morini, G.; Bertoni, S.; Ballabeni, V.; Barocelli, E.; Plazzi, P. V. Validation of a histamine H₃ receptor model through structure-activity relationships for classical H₃ antagonists. *Bioorg. Med. Chem.* **2005**, *13*, 5647–5657.
- (37) Rai, B. K.; Tawa, G. J.; Katz, A. H.; Humblet, C. Modeling G protein-coupled receptors for structure-based drug discovery using low-frequency normal modes for refinement of homology models: Application to H₃ antagonists. *Proteins: Struct., Funct., Bioinf.* **2010**, *78*, 457–473.
- (38) Axe, F. U.; Bembenek, S. D.; Szalma, S. Three-dimensional models of histamine H₃ receptor antagonist complexes and their pharmacophore. *J. Mol. Graphics Modell.* **2006**, *24*, 456–464.
- (39) Morini, G.; Comini, M.; Rivara, M.; Rivara, S.; Lorenzi, S.; Bordi, F.; Mor, M.; Flammini, L.; Bertoni, S.; Ballabeni, V.; Barocelli, E.; Plazzi, P. V. Dibasic non-imidazole histamine H₃ receptor antagonists with a rigid biphenyl scaffold. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 4063–4067.
- (40) Stark, H.; Sippl, W.; Ligneau, X.; Arrang, J. M.; Ganellin, C. R.; Schwartz, J. C.; Schunack, W. Different antagonist binding properties of human and rat histamine H₃ receptors. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 951–954.
- (41) Uveges, A. J.; Kowal, D.; Zhang, Y.; Spangler, T. B.; Dunlop, J.; Semus, S.; Jones, P. G. The role of transmembrane helix 5 in agonist binding to the human H₃ receptor. *J. Pharmacol. Exp. Ther.* **2002**, *301*, 451–458.
- (42) Yao, B. B.; Witte, D. G.; Miller, T. R.; Carr, T. L.; Kang, C. H.; Cassar, S.; Faghih, R.; Bennani, Y. L.; Surber, B. W.; Hancock, A. A.; Esbenschade, T. A. Use of an inverse agonist radioligand [³H]A-317920 reveals distinct pharmacological profiles of the rat histamine H₃ receptor. *Neuropharmacology* **2006**, *50*, 468–478.
- (43) Schlegel, B.; Laggner, C.; Meier, R.; Langer, T.; Schnell, D.; Seifert, R.; Stark, H.; Hölftje, H. D.; Sippl, W. Generation of a homology model of the human histamine H(3) receptor for ligand docking and pharmacophore-based screening. *J. Comput.-Aided Mol. Des.* **2007**, *21*, 437–453.
- (44) Levoine, N.; Calmels, T.; Poupardin-Olivier, O.; Labeeuw, O.; Danvy, D.; Robert, P.; Berrebi-Bertrand, I.; Ganellin, C. R.; Schunack, W.; Stark, H.; Capet, M. Refined docking as a valuable tool for lead optimization: application to histamine H₃ receptor antagonists. *Arch. Pharm.* **2008**, *341*, 610–623.
- (45) Kim, S. K.; Fristrup, P.; Abrol, R.; Goddard, W. A., III. Structure-based prediction of subtype selectivity of histamine H₃ receptor selective antagonists in clinical trials. *J. Chem. Inf. Model.* **2011**, *51*, 3262–3274.
- (46) Kurczab, R.; Śliwa, P.; Rataj, K.; Kafel, R.; Bojarski, A. J. Salt Bridge in Ligand-Protein Complexes - Systematic Theoretical and Statistical Investigations. *J. Chem. Inf. Model.* **2018**, *58*, 2224–2238.
- (47) Peng, X.; Yang, L.; Liu, Z.; Lou, S.; Mei, S.; Li, M.; Chen, Z.; Zhang, H. Structural basis for recognition of antihistamine drug by human histamine receptor. *Nat. Commun.* **2022**, *13*, 6105.
- (48) Bicker, J.; Alves, G.; Fortuna, A.; Falcão, A. Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: A review. *Eur. J. Pharm. Biopharm.* **2014**, *87*, 409–432.
- (49) Chen, X.; Murawski, A.; Patel, K.; Crespi, C. L.; Balimane, P. V. A novel design of artificial membrane for improving the PAMPA model. *Pharm. Res.* **2008**, *25*, 1511–1520.
- (50) Tjølsen, A.; Berge, O. G.; Hunskaar, S.; Rosland, J. H.; Hole, K. The formalin test: an evaluation of the method. *Pain* **1992**, *51*, 5–17.
- (51) Vierck, C. J.; Yeziarski, R. P.; Light, A. R. Long-lasting hyperalgesia and sympathetic dysregulation after formalin injection into the rat hind paw. *Neuroscience* **2008**, *153*, 501–506.
- (52) Salinas-Abarca, A. B.; Avila-Rojas, S. H.; Barragán-Iglesias, P.; Pineda-Farías, J. B.; Granados-Soto, V. Formalin injection produces long-lasting hypersensitivity with characteristics of neuropathic pain. *Eur. J. Pharmacol.* **2017**, *797*, 83–93.
- (53) Frias, B.; Merighi, A. Capsaicin, Nociception and Pain. *Molecules* **2016**, *21*, 797.
- (54) Joseph, E. K.; Levine, J. D. Comparison of Oxaliplatin- and Cisplatin-Induced Painful Peripheral Neuropathy in the Rat. *J. Pain* **2009**, *10*, 534–541.
- (55) Chambers, J. E.; Chambers, H. W.; Funck, K. E.; Meek, E. C.; Pringle, R. B.; Ross, M. K. Efficacy of novel phenoxyalkyl pyridinium oximes as brain-penetrating reactivators of cholinesterase inhibited by surrogates of sarin and VX. *Chem.-Biol. Interact.* **2016**, *259*, 154–159.
- (56) Sheldrick, G. M. SHELXT - Integrated space-group and crystal-structure determination. *Acta Crystallogr., Sect. A: Found. Crystallogr.* **2015**, *71*, 3–8.
- (57) Sheldrick, G. M. A short history of SHELX. *Acta Crystallogr., Sect. A: Found. Crystallogr.* **2008**, *64*, 112–122.
- (58) Farrugia, L. J. WinGX suite for small-molecule single-crystal crystallography. *J. Appl. Crystallogr.* **1999**, *32*, 837–838.
- (59) Macrae, C. F.; Sovago, I.; Cottrell, S. J.; Galek, P. T. A.; McCabe, P.; Pidcock, E.; Platings, M.; Shields, G. P.; Stevens, J. S.; Towler, M.; Wood, P. A. Mercury 4.0: from visualization to analysis, design and prediction. *J. Appl. Crystallogr.* **2020**, *53*, 226–235.
- (60) Nardelli, M. Modeling hydroxyl and water H atoms. *J. Appl. Crystallogr.* **1999**, *32*, 563–571.
- (61) Amata, E.; Dichiarà, M.; Gentile, D.; Marrazzo, A.; Turnaturi, R.; Arena, E.; La Mantia, A.; Tomasello, B. R.; Acquaviva, R.; Di Giacomo, C.; Rescifina, A.; Prezzavento, O. Sigma Receptor Ligands Carrying a Nitric Oxide Donor Nitrate Moiety: Synthesis, *In Silico*, and Biological Evaluation. *ACS Med. Chem. Lett.* **2020**, *11*, 889–894.
- (62) Dichiarà, M.; Artacho-Cordón, A.; Turnaturi, R.; Santos-Caballero, M.; González-Cano, R.; Pasquinnucci, L.; Barbaraci, C.; Rodríguez-Gómez, I.; Gómez-Guzmán, M.; Marrazzo, A.; Cobos, E. J.; Amata, E. Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation. *Eur. J. Med. Chem.* **2022**, *230*, No. 114091.
- (63) Amata, E.; Rescifina, A.; Prezzavento, O.; Arena, E.; Dichiarà, M.; Pittalà, V.; Montilla-García, Á.; Punzo, F.; Merino, P.; Cobos, E. J.; Marrazzo, A. (+)-Methyl (1R,2S)-2-[[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]methyl]-1-phenylcyclopropanecarboxylate [(+)-MR200] Derivatives as Potent and Selective Sigma Receptor Ligands: Stereochemistry and Pharmacological Properties. *J. Med. Chem.* **2018**, *61*, 372–384.
- (64) Amata, E.; Dichiarà, M.; Arena, E.; Pittalà, V.; Pistarà, V.; Cardile, V.; Graziano, A. C. E.; Fraix, A.; Marrazzo, A.; Sortino, S.; Prezzavento, O. Novel Sigma Receptor Ligand-Nitric Oxide Photodons: Molecular Hybrids for Double-Targeted Antiproliferative Effect. *J. Med. Chem.* **2017**, *60*, 9531–9544.
- (65) Rosier, N.; Grätz, L.; Schihada, H.; Möller, J.; İşbilir, A.; Humphrys, L. J.; Nagl, M.; Seibel, U.; Lohse, M. J.; Pockes, S. A Versatile Sub-Nanomolar Fluorescent Ligand Enables NanoBRET Binding Studies and Single-Molecule Microscopy at the Histamine H₃ Receptor. *J. Med. Chem.* **2021**, *64*, 11695–11708.
- (66) Bartole, E.; Grätz, L.; Littmann, T.; Wifling, D.; Seibel, U.; Buschauer, A.; Bernhardt, G. UR-DEBa242: A Py-5-Labeled Fluorescent Multipurpose Probe for Investigations on the Histamine H₃ and H₄ Receptors. *J. Med. Chem.* **2020**, *63*, 5297–5311.
- (67) Baumeister, P.; Erdmann, D.; Biselli, S.; Kagermeier, N.; Elz, S.; Bernhardt, G.; Buschauer, A. [³H]UR-DE257: development of a tritium-labeled squaramide-type selective histamine H₂ receptor antagonist. *ChemMedChem* **2015**, *10*, 83–93.
- (68) Igel, P.; Schnell, D.; Bernhardt, G.; Seifert, R.; Buschauer, A. Tritium-labeled N¹-[3-(1H-imidazol-4-yl)propyl]-N²-propionylguani-

dine ($[^3\text{H}]$ UR-PI294), a high-affinity histamine H_3 and H_4 receptor radioligand. *ChemMedChem* **2009**, *4*, 225–231.

(69) Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50 per cent inhibition (I_{50}) of an enzymatic reaction. *Biochem. Pharmacol.* **1973**, *22*, 3099–3108.

(70) Varadi, M.; Anyango, S.; Deshpande, M.; Nair, S.; Natassia, C.; Yordanova, G.; Yuan, D.; Stroe, O.; Wood, G.; Laydon, A.; Židek, A.; Green, T.; Tunyasuvunakool, K.; Petersen, S.; Jumper, J.; Clancy, E.; Green, R.; Vora, A.; Lutfi, M.; Figurnov, M.; Cowie, A.; Hobbs, N.; Kohli, P.; Kleywegt, G.; Birney, E.; Hassabis, D.; Velankar, S. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. *Nucleic Acids Res.* **2022**, *50*, D439–D444.

(71) Jumper, J.; Evans, R.; Pritzel, A.; Green, T.; Figurnov, M.; Ronneberger, O.; Tunyasuvunakool, K.; Bates, R.; Židek, A.; Potapenko, A.; Bridgland, A.; Meyer, C.; Kohl, S. A. A.; Ballard, A. J.; Cowie, A.; Romera-Paredes, B.; Nikolov, S.; Jain, R.; Adler, J.; Back, T.; Petersen, S.; Reiman, D.; Clancy, E.; Zielinski, M.; Steinegger, M.; Pacholska, M.; Berghammer, T.; Bodenstein, S.; Silver, D.; Vinyals, O.; Senior, A. W.; Kavukcuoglu, K.; Kohli, P.; Hassabis, D. Highly accurate protein structure prediction with AlphaFold. *Nature* **2021**, *596*, 583–589.

(72) Berman, H. M. The Protein Data Bank. *Nucleic Acids Res.* **2000**, *28*, 235–242.

(73) Burley, S. K.; Bhikadiya, C.; Bi, C.; Bittrich, S.; Chen, L.; Crichtow, G. V.; Christie, C. H.; Dalenberg, K.; Di Costanzo, L.; Duarte, J. M.; Dutta, S.; Feng, Z.; Ganesan, S.; Goodsell, D. S.; Ghosh, S.; Green, R. K.; Guranović, V.; Guzenko, D.; Hudson, B. P.; Lawson, C. L.; Liang, Y.; Lowe, R.; Namkoong, H.; Peisach, E.; Persikova, I.; Randle, C.; Rose, A.; Rose, Y.; Sali, A.; Segura, J.; Sekharan, M.; Shao, C.; Tao, Y. P.; Voigt, M.; Westbrook, J. D.; Young, J. Y.; Zardecki, C.; Zhuravleva, M. RCSB Protein Data Bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences. *Nucleic Acids Res.* **2021**, *49*, D437–D451.

(74) Schmidt, H. R.; Zheng, S.; Gulpinar, E.; Koehl, A.; Manglik, A.; Kruse, A. C. Crystal structure of the human σ_1 receptor. *Nature* **2016**, *532*, 527–530.

(75) Schmidt, H. R.; Betz, R. M.; Dror, R. O.; Kruse, A. C. Structural basis for σ_1 receptor ligand recognition. *Nat. Struct. Mol. Biol.* **2018**, *25*, 981–987.

(76) *Schrodinger Release 2017–3; LigPrep.* 2017.

(77) Shelley, J. C.; Cholleti, A.; Frye, L. L.; Greenwood, J. R.; Timlin, M. R.; Uchimaya, M. Epik: A software program for pK_a prediction and protonation state generation for drug-like molecules. *J. Comput.-Aided Mol. Des.* **2007**, *21*, 681–691.

(78) Madhavi Sastry, G.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. *J. Comput.-Aided Mol. Des.* **2013**, *27*, 221–234.

(79) Harder, E.; Damm, W.; Maple, J.; Wu, C.; Reboul, M.; Xiang, J. Y.; Wang, L.; Lupyan, D.; Dahlgren, M. K.; Knight, J. L.; Kaus, J. W.; Cerutti, D. S.; Krilov, G.; Jorgensen, W. L.; Abel, R.; Friesner, R. A. OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. *J. Chem. Theory Comput.* **2016**, *12*, 281–296.

(80) Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. *J. Med. Chem.* **2006** *Oct* **19**, *49*, 6177–6196.

(81) Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. *J. Med. Chem.* **2004**, *47*, 1750–1759.

(82) Murphy, R. B.; Philipp, D. M.; Friesner, R. A. A Mixed Quantum Mechanics/Molecular Mechanics (QM/MM) Method for

Large-Scale Modeling of Chemistry in Protein Environments. *J. Comput. Chem.* **2000**, *21*, 1442–1457.

(83) Cho, A. E.; Guallar, V.; Berne, B. J.; Friesner, R. Importance of accurate charges in molecular docking: Quantum Mechanical/Molecular Mechanical (QM/MM) approach. *J. Comput. Chem.* **2005**, *26*, 915–931.

(84) Mogilski, S.; Kubacka, M.; Łażewska, D.; Więcek, M.; Gluch-Lutwin, M.; Tyszcza-Czochara, M.; Bukowska-Strakova, K.; Filipek, B.; Kieć-Kononowicz, K. Aryl-1,3,5-triazine ligands of histamine H_4 receptor attenuate inflammatory and nociceptive response to carrageen, zymosan and lipopolysaccharide. *Inflammation Res.* **2017**, *66*, 79–95.

(85) Salat, K.; Cios, A.; Wyska, E.; Salat, R.; Mogilski, S.; Filipek, B.; Więckowski, K.; Malawska, B. Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice. *Pharmacol., Biochem. Behav.* **2014** *Jul*, *122*, 173–181.

(86) Milano, J.; Oliveira, S. M.; Rossato, M. F.; Sauzem, P. D.; Machado, P.; Beck, P.; Zanatta, N.; Martins, M. A. P.; Mello, C. F.; Rubin, M. A.; Ferreira, J.; Bonacorso, H. G. Antinociceptive effect of novel trihalomethyl-substituted pyrazoline methyl esters in formalin and hot-plate tests in mice. *Eur. J. Pharmacol.* **2008**, *581*, 86–96.

(87) Pavao-de-Souza, G. F.; Zarpelon, A. C.; Tedeschi, G. C.; Mizokami, S. S.; Sanson, J. S.; Cunha, T. M.; Ferreira, S. H.; Cunha, F. Q.; Casagrande, R.; Verri, W. A., Jr. Acetic acid- and phenyl-pbenzoquinone-induced overt pain-like behavior depends on spinal activation of MAP kinases, PI_3K and microglia in mice. *Pharmacol., Biochem. Behav.* **2012** *May*, *101*, 320–328.

(88) Lopes, S. C.; da Silva, A. V. L.; Arruda, B. R.; Morais, T. C.; Rios, J. B.; Trevisan, M. T. S.; Rao, V. S.; Santos, F. A. Peripheral antinociceptive action of mangiferin in mouse models of experimental pain: role of endogenous opioids, K(ATP)-channels and adenosine. *Pharmacol., Biochem. Behav.* **2013**, *110*, 19–26.

(89) Mogilski, S.; Kubacka, M.; Redzicka, A.; Kazek, G.; Dudek, M.; Malinka, W.; Filipek, B. Antinociceptive, anti-inflammatory and smooth muscle relaxant activities of the pyrrolo[3,4-d]pyridazinone derivatives: Possible mechanisms of action. *Pharmacol., Biochem. Behav.* **2015** *Jun*, *133*, 99–110.

(90) Sánchez-Fernández, C.; Montilla-García, Á.; González-Cano, R.; Nieto, F. R.; Romero, L.; Artacho-Cordón, A.; Montes, R.; Fernández-Pastor, B.; Merlos, M.; Baeyens, J. M.; Entrena, J. M.; Cobos, E. J. Modulation of peripheral μ -opioid analgesia by σ_1 receptors. *J. Pharmacol. Exp. Ther.* **2014**, *348*, 32–45.

(91) Ruiz-Cantero, M. C.; Cortés-Montero, E.; Jain, A.; Montilla-García, Á.; Bravo-Caparrós, I.; Shim, J.; Sánchez-Blázquez, P.; Woolf, C. J.; Baeyens, J. M.; Cobos, E. J. The sigma-1 receptor curtails endogenous opioid analgesia during sensitization of TRPV1 nociceptors. *Br. J. Pharmacol.* **2023**, *180*, 1148–1167.

(92) Salat, K.; Kołaczowski, M.; Furgała, A.; Rojek, A.; Śniecikowska, J.; Varney, M. A.; Newman-Tancredi, A. Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT_{1A} receptor selective agonist, NLX-112 in mouse models of pain. *Neuropharmacology* **2017** *Oct*, *125*, 181–188.

(93) Zimmermann, M. Ethical guidelines for investigations of experimental pain in conscious animals. *Pain* **1983** *Jun*, *16*, 109–110.

(94) Bennett, G. J.; Xie, Y. K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. *Pain* **1988** *Apr*, *33*, 87–107.

(95) Popiołek-Barczyk, K.; Łażewska, D.; Latacz, G.; Olejarz, A.; Makuch, W.; Stark, H.; Kieć-Kononowicz, K.; Mika, J. Antinociceptive effects of novel histamine H_3 and H_4 receptor antagonists and their influence on morphine analgesia of neuropathic pain in the mouse. *Br. J. Pharmacol.* **2018**, *175*, 2897–2910.